Antitumor composition
Through the recombinant adenovirus system, the problems of IL-12 toxicity and C-met overexpression in tumors were solved, and efficient anti-cancer effects and immune function recovery were achieved.
Patent Information
- Application Number
- CN201980046531.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2018-07-10
- Filing Date
- 2019-07-10
- Publication Date
- 2024-11-08
- Estimated Expiration
- 2039-07-10
AI Technical Summary
Among the existing tumor immunotherapy, the clinical application of IL-12 has problems with systemic cytokine-associated toxicity, and the overexpression of C-met causes rapid proliferation and migration of cancer cells, which is difficult to eliminate through immune responses, and it is difficult to control tumors by a single therapy.
Using a recombinant adenovirus system, co-expressing interleukin 12 (IL-12) and nucleic acid molecules that inhibit C-met expression are used to restore immune function in the tumor environment through the gene delivery system and enhance anti-cancer effects.
It significantly enhances the anti-cancer effect, inhibits tumor growth and migration, reduces the need for therapeutic dose, avoids the systemic toxicity of IL-12 when used alone, and improves the anti-tumor immune response.
Smart Images

Figure CN112513281B_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to a composition for anti-tumor or anti-tumor immunity enhancement, which comprises a recombinant adenovirus for co-expressing interleukin 12 (IL-12) and a nucleic acid molecule for inhibiting the expression of tyrosine kinase Met (C-met). Background Art
[0002] Tumor immunotherapy is a method of inducing an immune response against tumors by enhancing the overall immune function of the human body and treating tumors through it. Research on tumor immunotherapy is actively underway. However, an immunosuppressive environment is almost always formed at the stage of generating cancer, so it is difficult to easily remove tumors even if the human immune system is actively working. Tumor cells themselves express many abnormal antigens. These antigens cause eradication reactions through immune surveillance, allowing tumor cells to escape immune surveillance even if the human immune system is active. In addition, it has been found that this phenomenon is mediated by various factors produced by tumor cells. It is reported that tumor tissue can produce immunosuppressive molecules such as vascular endothelial growth factor (VEGF), tumor growth factor (TGF)-β and interleukin (IL)-10, and regulatory T cells penetrate immunosuppressive tumors. Further, the stimulation of activated T cells to the expression of an inhibitory receptor called PD-1 continues to increase, and in the case of cancer cells, PD-L1, a ligand that specifically binds to PD-1, is expressed in large quantities to inactivate activated T cells to avoid immune responses, thereby generating an immunosuppressive microenvironment and immune tolerance in tumors.
[0003] Recent studies have shown that inhibitors of immune checkpoints that can inhibit PD-1, which are involved in inhibiting T cell activity, induce strong anti-tumor immune responses. Therefore, overcoming immune surveillance avoidance is the main strategy for immunotherapy. Therefore, as a way to overcome these limitations, research is actively being conducted to introduce cytokine genes with immune-boosting effects directly into cancer cells to produce and secrete cytokines from cancer cells and thus specifically eliminate cancer cells by inducing anti-tumor immune responses. Among the immune-enhancing cytokine genes whose anti-tumor effects have been reported so far, interleukin 12 (IL-12) is one of the most effective and promising cytokines.
[0004] As a heterodimeric protein containing 40kDa and 35kDa subunits linked by disulfide bonds, interleukin 12 (IL-12) is secreted from antigen presenting cells (APCs), such as activated macrophages, monocytes, dendritic cells, and activated B lymphocytes, and directly acts on T cells and NK cells, which can effectively eliminate cancer cells to activate T cells and NK cells and induce the secretion of IFN-γ, as well as enhance the killing ability of T cells and NK cells against cancer cells. Local expression of IL-12 sensitizes tumor cells to T cell-mediated cytotoxicity, thereby inhibiting tumor growth and establishing systemic immunity.
[0005] However, the clinical application of IL-12 is difficult because the administration of IL-12 may cause systemic cytokine-related toxicity, thus limiting the acceptable dose for patients. In addition, due to the reduction of IFN-γ and TNF-β expression, it leads to overall downregulation of immune action, increased IL-10 expression in patient serum, and IL-12 polarization from Th1 immunity to Th2 immunity. Therefore, IL-12 is sometimes administered repeatedly. These clinical results indicate the limitations of IL-12 as a monotherapy for the treatment of cancer.
[0006] Recently, research on growth factors and their receptors as biological indicators reflecting the degree of malignancy is underway. Among them, research on C-met, a member of the tyrosine kinase receptor family, is actively underway. C-met acts as a receptor for hepatocyte growth factor / scatter factor (HGF / SF) and is overexpressed in a variety of cancers. Most patients with overexpression of C-met have a poor prognosis for cancer treatment.
[0007] Overexpression of C-met enhances mitosis and cell motility, inhibits apoptosis, forms blood vessels, and induces invasion and migration into the extracellular matrix (ECM) due to the HGF / SF-Met signaling system, i.e., causes an increase in malignant tumors. Since the rapid proliferation and migration of cancer cells induced by overexpression of C-met exceed the removal rate of cancer cells in the immune system, it is difficult to eliminate cancer cells by immune response. In addition, since the center of the immune response in the tumor microenvironment is severely inclined to suppression as the tumor size increases, it is more difficult to control tumor cells using a single therapy, and the anti-tumor effect cannot be improved by anti-tumor immunotherapy.
[0008] Therefore, developing anticancer therapies that do not have side effects that depend on the dose, etc., while having better anticancer effects by improving anti-tumor immunity remains a task to be solved in the art. Summary of the invention
[0009] Technical issues
[0010] Therefore, the present invention was proposed in view of the above problems, and the present inventors attempted to develop a therapeutic target capable of reducing the dose while having an excellent anti-tumor effect, and proposed a method for more effectively treating cancer by using a combination of therapeutic targets IL-12 and C-met. Compared with the case where only each therapeutic target is used alone, the present inventors confirmed that by using an adenovirus capable of expressing interleukin 12 in the treatment of cancer while suppressing overexpression of C-met, it is possible to suppress tumors and overcome immune surveillance to obtain a synergistic effect in the treatment of cancer, thereby completing the present invention.
[0011] Throughout this specification, many papers and patent documents are cited and citations are indicated. The disclosures of the cited papers and patent documents are incorporated into this specification by reference as a whole, thereby more clearly describing the level of the technical field to which the present invention belongs and the content of the present invention.
[0012] Technical Solution
[0013] According to one aspect of the present invention, the above and other objects can be achieved by providing a gene delivery system, including an interleukin 12 (IL-12) encoding gene; and a gene expressing an oligonucleotide that is complementary to the mRNA of C-met to inhibit C-met expression.
[0014] According to another aspect of the present invention, a pharmaceutical composition comprising a gene delivery system is provided, wherein the gene delivery system comprises: a nucleic acid sequence encoding interleukin 12 (IL-12); and a nucleic acid sequence expressing an oligonucleotide that complementarily binds to the C-met gene and inhibits the expression of C-met.
[0015] The gene delivery system can be an adenoviral system, and the adenoviral system can be a recombinant adenovirus or a recombinant adenoviral DNA.
[0016] The pharmaceutical composition may be an anti-cancer composition or a composition for enhancing anti-tumor immunity.
[0017] Beneficial Effects
[0018] The adenovirus system co-expressing interleukin 12 and C-met expression inhibitory nucleic acid molecules according to the present invention can restore immune function in the tumor environment to significantly enhance anti-cancer effects such as tumor remodeling and migration inhibition and tumor growth inhibition. Specifically, due to the co-expression of the two therapeutic genes, the adenovirus system can provide a significant synergistic effect in the treatment of cancer. BRIEF DESCRIPTION OF THE DRAWINGS
[0019] Figure 1 The diagram shows the structure of adenovirus plasmid DNA constructed according to an embodiment of the present invention.
[0020] Figure 2The diagram shows that the adenoviral plasmid DNA constructed according to an embodiment of the present invention can express mouse interleukin 12 (mIL-12) or human interleukin 12 (hIL-12) in cells.
[0021] Figure 3 The diagram shows that the adenovirus constructed according to an embodiment of the present invention increases the expression of interleukin 12 (IL-12) and inhibits the expression of C-met.
[0022] Figure 4 The diagram shows the anticancer adenovirus structure co-expressing IL-12 and shc-met constructed according to an embodiment of the present invention.
[0023] Figure 5a and 5b The in vivo anti-tumor effects of the anti-cancer adenovirus co-expressing IL-12 and shc-met according to the examples of the present invention in mouse-derived B16-F10 and CT26 cells are shown respectively.
[0024] Figure 6 The figure shows the in vivo anti-tumor effect of the anti-cancer adenovirus pDNA / PPA complex co-expressing IL-12 and shc-met according to an example of the present invention in mouse-derived B16-F10 cells.
[0025] Figure 7a and 7b The figure shows the in vivo IL-12 expression of the anticancer adenovirus co-expressing IL-12 and shc-met according to the embodiment of the present invention in the human lung cancer cell line H1975 ( Figure 7a ) and the ability to inhibit C-met expression in vivo ( Figure 7b ).
[0026] Figure 8a and 8b The graphs show the cancer cell killing ability of anticancer adenovirus expressing IL-12 and / or shc-met according to the embodiments of the present invention in the human lung cancer cell line H1975 under normoxic conditions (8a) and hypoxic conditions (8b).
[0027] Figure 9a , 9b , 9c and 9d illustrate the inhibitory effects of anticancer adenovirus expressing IL-12 and / or shc-met on HUVEC cell migration (9a and 9b) and invasion (9c and 9d) according to an embodiment of the present invention.
[0028] Fig.10 The diagram shows that tumor cell migration is inhibited in HUVEC cells through endothelial to mesenchymal transition (Endo-MT) inhibition by anticancer adenovirus expressing IL-12 and / or shc-met according to an embodiment of the present invention.
[0029] Fig.11 The anti-tumor effect of anti-cancer adenovirus expressing IL-12 and / or shc-met in a human xenograft tumor model (H1975) according to an embodiment of the present invention is shown.
[0030] Fig.12 The structure of a gene delivery system for co-expressing IL-12 and a CRISPR / Cas system including a C-met-targeted guide RNA according to an embodiment of the present invention is schematically illustrated.
[0031] Fig.13a , 13b and 13c illustrate the intercellular IL-12 expression effect (13a) and C-met inhibition effect (13b and 13c) by anticancer viruses co-expressing IL-12 and Lbcpf1-crMET according to an embodiment of the present invention.
[0032] Fig.14 The graph shows the anti-tumor effect of anti-cancer virus co-expressing IL-12 and Lbcpf1-crMET in a human xenograft tumor model (H1975) according to an embodiment of the present invention. DETAILED DESCRIPTION
[0033] According to one aspect of the present invention, the present invention provides a gene delivery system, which includes a gene encoding interleukin 12 (IL-12); and a gene expressing an oligonucleotide that complementarily binds to the C-met gene to inhibit the expression of C-met.
[0034] According to another aspect of the present invention, the present invention provides an anti-cancer composition comprising a gene delivery system, the system comprising an interleukin 12 (IL-12) encoding gene; and a gene expressing an oligonucleotide that complementarily binds to the C-met gene to inhibit C-met expression; an anti-metastatic composition for cancer cells comprising the gene delivery system; or a pharmaceutical composition for enhancing anti-tumor immunity comprising the gene delivery system.
[0035] According to another aspect of the present invention, the present invention provides the use of a gene delivery system, which includes a gene encoding interleukin 12 (IL-12); and a gene expressing an oligonucleotide as an anticancer agent, which oligonucleotide complementarily binds to the C-met gene to inhibit the expression of C-met.
[0036] According to another aspect of the present invention, a method for treating cancer is provided, which comprises administering a gene delivery system comprising a gene encoding interleukin 12 (IL-12); and a gene expressing an oligonucleotide that complementarily binds to the C-met gene to inhibit C-met expression, or a pharmaceutical composition comprising the gene delivery system to a subject.
[0037] In the present invention, the term "gene delivery system" refers to a vector system for delivering genes into cells. In the present invention, unless otherwise specified, gene delivery system, adenovirus vector, adenovirus system or adenovirus vector system have the same meaning. The adenovirus system of the present invention includes adenovirus and adenovirus DNA (viral DNA). Preferably, the adenovirus system can be a recombinant adenovirus or recombinant adenovirus DNA for enhancing anti-cancer or anti-tumor immunity.
[0038] The adenovirus system may include a genome sequence of an adenovirus, so that an adenovirus is generated by an adenovirus or a recombinant DNA delivered to a cell, thereby having an anti-cancer or anti-tumor immune effect. In the present invention, since the genes for expressing IL-12 and shc-met, respectively, can be inserted into the adenovirus genome and can be delivered to cells in the form of an adenovirus itself or its recombinant DNA, unless otherwise specified, throughout the present invention, adenovirus includes both recombinant adenovirus and recombinant adenovirus DNA.
[0039] According to a preferred embodiment of the present invention, the adenovirus system of the present invention can be an oncolytic adenovirus (oAd) that specifically proliferates only in tumors and selectively kills tumor cells. In this specification, "oncolytic adenovirus" can be used interchangeably with terms such as anticancer virus, oAd or tumor killing virus. All oncolytic adenoviruses that are genetically modified by conventional techniques used in the field to which the present invention belongs are included in the adenovirus system of the present invention. For example, E1A and / or E1B can be removed from the adenovirus genome so that it only proliferates in cancer cells and does not proliferate in normal cells, or the target sequence of the viral protein can be changed to use a protease secreted from cancer cells, or the sequence expressing the ligand can be inserted into the viral genome to express a receptor ligand that binds to a receptor (e.g., EGFR) present in cancer cells.
[0040] In addition, in order to enhance the killing ability of cancer cells, the TRAIL gene can be inserted into the tumor-selective oncolytic adenovirus of the present invention so that cell death occurs well, or the IFN gene can be applied to the tumor-selective oncolytic adenovirus to be inserted into cancer cells and effectively expressed therein, thereby causing an immune response.
[0041] The recombinant adenovirus used in the present invention includes a promoter operable in an animal cell (preferably a mammalian cell). Promoters suitable for the present invention include promoters derived from mammalian viruses and promoters derived from mammalian cell genomes. The transgene inserted into the recombinant adenovirus is preferably inserted into an expression cassette of a promoter-transgene poly A sequence. In this case, as a promoter, the gene expression control sequence of the present invention (HRE-TERT, HRE-E2F, HRE-TERT-E2F, HRE-E2F-TERT, HRE-E2F-5myc-TERT, and HRE can be included twice), or a universal promoter can be used.
[0042] The general promoter in conjunction with the transgene is preferably operated in an animal cell (more preferably a mammalian cell) to control the transcription of the transgene. Universal promoters include promoters derived from mammalian viruses and promoters derived from mammalian cell genomes. Examples of universal promoters include U6 promoters, H1 promoters, cytomegalovirus (CMV) promoters, adenovirus late promoters, vaccinia virus 7.5K promoters, SV40 promoters, HSV tk promoters, RSV promoters, EF1α promoters, metallothionein promoters, β-actin promoters, human IL-2 gene promoters, human IFN gene promoters, human IL-4 gene promoters, human lymphotoxin gene promoters, human GM-CSF gene promoters, inducible promoters, tumor cell-specific promoters (e.g., TERT promoter, PSA promoter, PSMA promoter, CEA promoter, E2F promoter, and AFP promoter) and tissue-specific promoters (e.g., albumin promoters), but the present disclosure is not limited thereto. Preferably, the expression construct for expressing the transgene includes a polyadenylation sequence bound to the downstream of the transgene. The polyadenylation sequence includes the bovine growth hormone terminator (Gimmi, ER et al., Nucleic Acids Res. 17: 6983-6998 (1989)), the polyadenylation sequence derived from SV40 (Schek, N et al., Mol. Cell Biol. 12: 5386-5393 (1992)), HIV-1 polyA (Klasens, BIF et al., Nucleic Acids Res. 26: 1870-1876 (1998)), β-globin polyA (Gil, A et al., Cell 49: 399-406 (1987)), HSV TK polyA (Cole, CN and TP Stacy, Mol. Cell. Biol. 5:2104-2113 (1985)) or polyomavirus polyA (Batt, DB and GG Carmichael, Mol. Cell. Biol. 15:4783-4790 (1995)), but the present disclosure is not limited thereto.
[0043] In the recombinant adenovirus used in the present invention, the IL-12 gene sequence and the sequence expressing the RNA that inhibits C-met are operably linked to the promoter. In this specification, the term "operably linked" refers to the functional connection between a nucleic acid expression control sequence (e.g., a promoter, a signal sequence, or an array of transcriptional regulatory factor binding sites) and another nucleic acid sequence. Therefore, the regulatory sequence controls the transcription and / or translation of different nucleic acid sequences.
[0044] The recombinant adenovirus of the present invention may additionally include antibiotic resistance genes and reporter genes (e.g., green fluorescent protein (GFP), luciferase, and β-glucuronidase) as selectable markers. Antibiotic resistance genes include those commonly used in the art, and may be, for example, resistance genes for ampicillin, gentamicin, carbenicillin, chloramphenicol, streptomycin, kanamycin, geneticin, neomycin, or tetracycline, preferably a neomycin resistance gene. Selectable markers may be expressed by a separate promoter, an internal ribosome entry site (IRES), or an expression system connected by a 2A system, and the IRES used in the present invention is a regulatory sequence found in the RNA of several viruses and cells (McBratney et al., Current Opinion in Cell Biol ogy 5:961 (1993)). In addition, a "2A peptide" refers to a sequence encoding a small (18-22 amino acid) peptide that can be cleaved, which allows for efficient and consistent expression of discrete protein products within a single coding sequence. For example, 2A peptides from viruses such as foot-and-mouth disease virus (F2A), equine rhinitis virus, porcine Teschovirus-1 (P2A), or Thosea asigna virus (T2A) or any of the 2A peptides described by Szymczak-Workman, A. et al. in "Design and Construction of 2A Peptide-Linked Multicistronic Vectors" can be used.
[0045] The present invention includes an interleukin 12 (IL-12) encoding gene; and a gene expressing an oligonucleotide that is complementary to the mRNA of C-met (tyrosine kinase Met) and inhibits the expression of C-met, and provides a synergistic effect in enhancing anti-cancer and anti-tumor immunity by co-expressing the two genes. In addition, the present technology is remarkable in that it can provide excellent therapeutic effects despite the administration of a small amount of IL-12, and solves the problem of side effects caused by the administration of conventional cytokines.
[0046] In the present specification, the term "interleukin 12 (IL-12)" refers to a heterodimeric cytokine formed by a 40kDa subunit (p40 subunit) and a 35kDa subunit (p35 subunit) bound by a disulfide bond. IL-12 is produced by antigen presenting cells (such as macrophages) and binds to receptors on the cell surface of activated T cells, B cells and NK cells. IL-12 promotes the proliferation of T cells and NK cells; enhances the cytotoxic effects of T cells, NK cells and macrophages; induces the production of IFN-γ, TNF-α and GM-CSF; and induces Th1 cell activation. In addition, IL-12 is recognized as an important auxiliary stimulator for the proliferation of Th1 clones and is known to increase the production of IgG2a antibodies in serum. In the present invention, the terms "p35 subunit" and "p40 subunit" include not only the subunits exemplified in the embodiments, but also all analogs of the subunits that can perform the unique functions of each subunit.
[0047] The adenovirus system of the present invention comprises a gene encoding IL-12 in an expressible form and secretes IL-12 after infecting tumor cells to induce a strong anti-tumor immune response.
[0048] The adenovirus system of the present invention can include the IL-12A (p35) gene and the IL-12B (p40) gene as subunits for expressing IL-12A (p35) and IL-12B (p40), thereby effectively expressing IL-12. In addition, a linker sequence can be additionally included between the IL-12A (p35) gene sequence and the IL-12B (p40) gene sequence for connecting the two subunits, or an internal ribosome entry site (IRES) sequence for improving protein expression efficiency can also be included.
[0049] A linker refers to any sequence that can be included between two genes, and in the present invention, a linker refers to a sequence that can be included between the IL-12A (p35) gene and the IL-12B (p40) gene. Linkers include all conventional linker sequences or randomly designed sequences known to be inserted between genes, and any linker can be included in the present invention as long as they do not adversely affect the expression of IL-12 or impair the functionality of IL-12. For example, an analog may be a sequence of sequence ID number 19, but the present invention is not limited thereto.
[0050] The amino acid sequence of "IL-12A subunit (p35 subunit)" that can be used in the present invention can be those described in GenBank Accession No. AAD56385 (when it is necessary to express the amino acid sequence of mouse p35, GenBank Accession No. AAA39292). In addition, as a sequence encoding an IL-12A subunit, the IL-12A (p35) gene can be a nucleotide sequence corresponding to the coding sequence (CDS) in the sequence described in GenBank Accession No. AF180562 (when it is necessary to use a mouse sequence, it refers to the CDS sequence in the sequence described in M86672). In addition, the IL-12A (p35) gene can have the sequence of Sequence ID No. 1 or Sequence ID No. 4 used in the embodiments of the present invention (in the case of mice, the sequence of Sequence ID No. 7).
[0051] The amino acid sequence of "IL-12B subunit (p40 subunit)" that can be used in the present invention can be those described in GenBank Accession No. AAD56386 (when it is necessary to express the amino acid sequence of mouse p40, GenBank Accession No. AAA39296). In addition, as a sequence encoding the IL-12B subunit, the IL-12B (p40) gene can be a nucleotide sequence corresponding to the coding sequence (CDS) in the sequence described in GenBank Accession No. AF180563 (when it is necessary to use a mouse sequence, it refers to the CDS sequence in the sequence described in M86671). In addition, the IL-12A (p35) gene can have the sequence of Sequence ID No. 2 or Sequence ID No. 5 used in the embodiments of the present invention (in the case of mice, the sequence of Sequence ID No. 8).
[0052] In the examples of the present invention, it was confirmed that IL-12 can be expressed in tumor cells by using the IL-12 gene of sequence ID No. 3 or sequence ID No. 6 (sequence ID No. 9 in the case of mice), and in particular, when expressed simultaneously with RNA for C-met, the expression level of 12 was significantly increased.
[0053] In the present specification, the term "C-met" is one of the tyrosine kinase receptor family. C-met acts as a receptor for hepatocyte growth factor / scatter factor (HGF / SF) and is overexpressed in a variety of cancers. Most patients with overexpression of c-met have a poor prognosis for cancer treatment. The C-met gene of the present invention can be a nucleotide sequence corresponding to the coding sequence (CDS) in the mRNA sequence disclosed in GenBank Accession No. gi:4557746 (when it is necessary to use a mouse sequence, it refers to the CDS sequence in the sequence described in Accession No. gi:146198695).
[0054] Overexpression of C-met increases mitosis and cell motility due to the HGF / SF-Met signaling system, and induces invasion and migration into the extracellular matrix, thereby increasing the malignancy of cancer. Therefore, in the treatment of cancer, inhibiting C-met expression is a very important issue. The present invention inhibits the expression of C-met using oligonucleotides complementary to the mRNA of C-met, and inhibits the expression of C-met, and in particular, it is confirmed that when the oligonucleotide is co-expressed with IL-12, the inhibition of C-met expression is significantly enhanced compared to the group that only inhibits the expression of C-met.
[0055] In the examples, the mRNA of C-met that is the inhibition target in the present invention may be the sequence shown in SEQ ID No. 10 (SEQ ID No. 11 in the case of mice).
[0056] The oligonucleotide that binds to the C-met gene to inhibit C-met expression can be one or more selected from shRNA, miRNA, siRNA, antisense oligonucleotide, ribozyme, deoxyribozyme, triple-stranded oligonucleotide (TFO), peptide nucleic acid (PNA) and CRISPR guide RNA.
[0057] The oligonucleotide sequence for inhibiting C-met expression may include a sequence identical or complementary to a portion of the C-met mRNA sequence of Sequence ID No. 10, preferably includes a sequence identical or complementary to a sequence of 4 or more consecutive nucleotides in the sequence of Sequence ID No. 10.
[0058] In the examples of the present invention, it was confirmed that the expression of C-met in tumor cells can be effectively inhibited by using shRNA as an oligonucleotide, the shRNA including a sequence complementary to the mRNA of C-met and capable of inhibiting the expression of C-met.
[0059] In the present invention, "shRNA" (small hairpin RNA or short hairpin RNA) of artificial RNA molecules with hairpin structures is used to inhibit the expression of target genes by RNA interference. shRNA is mainly transported into cells via plasmids, bacteria or viral vectors. shRNA has the advantages of relatively low degradation rate and turnover rate.
[0060] In the Examples of the present invention, it was demonstrated that the viral system of the present invention effectively inhibited the expression of C-met by using shRNA encoded by the gene of Sequence ID No. 12 (human) or Sequence ID No. 14 (mouse), "Hshc-met (sequence targeting Sequence ID No. 13)" or "shc-met (sequence targeting Sequence ID No. 15)" as shRNA to inhibit the expression of C-met.
[0061] The oligonucleotide that binds to the C-met gene to inhibit C-met expression may be a guide RNA for CRISPR. When the gene delivery system of the present invention expresses the CRISPR-CAS system, it may also include a sequence that expresses the Cas protein.
[0062] In the present invention, the "CRISPR-CAS system" refers to a technology that recognizes a specific nucleotide sequence present on a target DNA and cuts the DNA with a restriction enzyme to correct a gene. In the present invention, the CRISPR-CAS system is characterized in that when a sequence expressing a guide RNA for a target gene C-met is inserted into an adenovirus system and the expressed guide RNA hybridizes with the target C-met, the target site is cut using a Cas protein to inhibit the expression of C-met.
[0063] Unless otherwise specified, the method of constructing the CRISPR-CAS system, the type of restriction enzyme protein to be used in the CRISPR-CAS system, etc. can be used using techniques commonly used in the technical field of the present invention.
[0064] The Cas protein used in the present invention can be a Cas9 or Cas12 protein. The Cas9 or Cas12 (also referred to as Cas12a or Cpf1) protein used in the present invention can be used without restriction, as long as it is a Cas protein commonly used to implement the CRISPR / Cas system in the technical field of the present invention. In addition, examples of specific types of Cas9 or Cas12 proteins are shown in Table 1 below, but are not limited thereto. The references listed in Table 1 are included in the specification of the present invention as a whole.
[0065] [Table 1]
[0066]
[0067]
[0068] Cpf1 is a CRISPR / Cas system and is classified as a Class 2 Type 5 CRISPR / Cas system. Cpf1 works as a single subunit effector module like Cas9, but is slightly different from Cas9 in functionality, so while Cas9 requires tracrRNA to cut genes, Cpf1 does not. In the case of Cas9, genes in the region of the protospacer adjacent motif (PAM) containing a large number of guanines are excised, while Cpf1 can efficiently cut regions with a large number of thymines. In addition, Cpf1 has the property of generating 4 to 5 nucleotide overhangs when cutting genes. Due to these various characteristics and structural differences, even though the operating efficiency of Cpf1 is slightly lower than that in Cas9, it still exhibits higher accuracy.
[0069] The promoter used to express the CRISPR-CAS system of the present invention can be any promoter, without limitation, as long as it is used in the CRISPR / Cas system of the technical field to which the present invention belongs. For example, an RNA polymerase III promoter belonging to the type III class or a U6 promoter can be used. In this case, since the commonly used U6 promoter requires guanosine nucleotides to initiate transcription, the use of the U6 promoter can also limit the genomic targeting site to the GN. 19 NGG (Mali et al. (2013) Science 339:823-826; Ding et al. (2013) Cell Stem Cell 12:393-394). T7, T3 or SP6 promoters can also be used in the vector system of the present invention (Adhya et al. (1981) Proc. Natl. Acad. Sci. USA 78:147-151; Melton et al. (1984) Nucleic Acids Res. 12:7035-7056; Pleiss et al. (1998) RNA 4:1313-1317).
[0070] In an embodiment of the present invention, it was confirmed that by using the 55th to 77th nucleotides in the human C-met mRNA with sequence ID No. 10 as the target sequence (sequence ID No. 17), and by using an adenovirus system including a gene with sequence ID No. 16 (expressing a guide RNA of CRISPR that can complementarily hybridize with the target sequence); and expressing a gene with sequence ID No. 18 of Lbcpf1, the expression of C-met can be effectively inhibited by the CRISPR-CAS system of crRNA-LbCpf1.
[0071] In an embodiment of the present invention, a recombinant adenovirus vector containing a gene sequence expressing LbCpf1 is used to express the CRISPR-CAS system, as shown in FIG13 .
[0072] In the present invention, the term "complementary" means not only 100% complementarity, but also includes incomplete complementarity sufficient to inhibit C-met gene expression through RNA interference mechanism, preferably 90% complementarity, more preferably 98% complementarity, and most preferably 100% complementarity. In this specification, when 100% complementarity is expressed, it is described as "complete complementarity".
[0073] According to an embodiment of the present invention, the shRNA sequence included in the adenovirus of the present invention includes a sequence complementary to some sequences of sequence ID No. 10, preferably a sequence complementary to the sequence from the 1987th nucleotide to the 2007th nucleotide of the C-met mRNA sequence of sequence ID No. 10.
[0074] According to a specific embodiment of the present invention, the shRNA as an oligonucleotide capable of inhibiting the expression of C-met may be encoded by the gene of Sequence ID No. 12 or Sequence ID No. 16 (in the case of mice, the gene of Sequence ID No. 14).
[0075] The "gene or gene sequence" used in the present invention is interpreted as including gene sequences that show substantial identity or substantial similarity with each sequence of the sequence number proposed in the present invention. When the sequence of the present invention and any other sequence are aligned as much as possible to correspond to each other, and when the aligned sequences are analyzed using an algorithm commonly used in the art, substantial identity refers to sequences that exhibit greater than 70% homology, preferably 80% homology, more preferably 90% homology, and most preferably 95% homology. Substantial similarity generally refers to the following situation L: changes in the IL-12 gene sequence (such as deletion or insertion of one or more bases) do not affect the purpose of the present invention to minimize homologous recombination with the recombinant vector system. Therefore, the IL-12 gene sequence of the present invention is not limited to the exemplified sequence list, and is interpreted as being included in the scope of the present invention as long as it does not substantially affect the activity of the desired final product of the present invention.
[0076] The adenovirus system of the present invention can achieve cancer treatment by using the genome backbone of adenovirus. Adenovirus is widely used as a gene delivery system due to its medium genome size, easy manipulation, high titer, wide range of target cells and excellent infectivity. Both ends of the genome contain 100 to 200bp of inverse terminal receptors (ITP), which are important components of DNA replication and packaging. The E1 region (E1A and E1B) of the genome encodes proteins that regulate transcription and host cell gene transcription. The E2 region (E2A and E2B) encodes proteins involved in viral DNA replication. Since it is known that cis only requires a small part of the adenovirus genome (Tooza, J., Molecular biology of DNA Tumor viruses, 2nd edition, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York (1981)), adenovirus has the ability to carry foreign DNA molecules.
[0077] In the genome of the adenovirus system of the present invention, the E1 and E3 regions may be deleted. Specifically, the adenovirus system of the present invention may include the E1A gene and the inactivated E1B 19 gene, the inactivated E1B 55 gene, or the inactivated E1B 19 gene and the E1B 55 gene.
[0078] In this specification, the term "inactivation" used in relation to a gene means that the transcription and / or translation of the gene is not performed normally, and the function of the normal protein encoded by the gene does not occur. For example, in the case of an inactivated E1B 19 gene, due to a mutation (replacement, addition, partial deletion or complete deletion) of the E1B 19 gene, active E1B 19 kDa protein cannot be produced. When E1B 19 is deleted, apoptosis can be increased, and when the E1B 55 gene is deleted, tumor cell specificity is exhibited (see patent application No. 2002-23760). In this specification, the term "deletion" used in relation to a gene or sequence has the meaning of including not only the complete deletion of the corresponding sequence but also the partial deletion thereof.
[0079] The recombinant adenovirus of the present invention may have a mutation in which the 45th Glu residue of the nucleotide sequence encoding the Rb binding site located in the E1A gene sequence is substituted with Gly and a mutation in which all of its 121st to 127th amino acid sequences are substituted with Gly.
[0080] According to an embodiment of the present invention, the recombinant adenovirus may include an E1A site, and the E1B 19kDa and E3 sites (ΔE3) therein may be deleted. The recombinant adenovirus including the E1A gene has a replicable property. The IL-12 gene and the C-met expression inhibition oligonucleotide may be inserted into the deleted E1 and E3 sites of the adenovirus, respectively.
[0081] The adenovirus system of the present invention may also include a biocompatible polymer to improve the intracellular delivery ability of the adenovirus or its viral DNA by being delivered into cells, or to increase the remaining time, etc. Specifically, the biocompatible polymer may be included in the system of the present invention in the form of a combination with the adenovirus or adenovirus plasmid DNA.
[0082] The biocompatible polymer may be any one as long as it can be used in a vector system for gene delivery in the technical field of the present invention.
[0083] For example, the biocompatible polymer of the present invention can be a pH-sensitive bioreducible polymer that includes (a) an immune response evasive portion, (b) a chargeable portion, and (c) a bioreducible portion that includes a disulfide bond.
[0084] The function of the immune response evasive part (a) is to allow the polymer-bound virus to avoid the in vivo immune response (including cellular and systemic immune response). The material that can be used for the immune response evasive part is specifically a polymer that can evade the in vivo immune response (including cellular and systemic immune response), more specifically PEG (polyethylene glycol), ethyleneoxy (such as polyethylene oxide, polypropylene oxide or its copolymer (polyethylene oxide-polypropylene oxide-polyethylene oxide copolymer)), polyphenylene ether, copolymer of PEG and ethyleneoxy, poly (methoxyethyl methacrylate), poly (methacryloyl phosphatidylcholine), perfluoropolyether, dextran or polyvinylpyrrolidone, more specifically PEG, ethyleneoxy or copolymer of PEG and ethyleneoxy, even more specifically PEG.
[0085] The charged part (b) can be combined with the surface or DNA of the virus with negative charge under the in vivo pH (particularly near the neutral pH) to make the polymer positively charged. Alternatively, in contrast to the above, depending on the chargeability of the viral surface or DNA, the charged part (b) can make the polymer negatively charged. Therefore, the charged part (b) includes materials that make the polymer positively or negatively charged. For example, when imparting a negative charge, a carboxylate group can be used in the charged part (b), and when imparting a positive charge, a monomer with a tertiary amine group or an amino group can be used for the charged part (b).
[0086] The bioreducible portion (c) including a disulfide bond can be included in the present invention without being limited to the type of monomer as long as it includes a disulfide bond.
[0087] The bioreducible portion (c) is reduced in vivo in an acidic environment, thereby converting disulfide bonds to sulfhydryl groups, thereby destroying the polymer structure and ultimately releasing the binding of naked virus or DNA to the polymer-virus complex or polymer-DNA complex.
[0088] In another embodiment, the biocompatible polymer of the present invention can include all polymers, nanomaterials, dendrimers and hydrogels. The biocompatible polymer is preferably selected from PEI-Arg-mPEG-SS-mPEG-Arg-PEI (PAPS), mPEG-PEI-g-Arg-SS-Arg-g-PEI-mPEG (PPSA), PICION (pegylated and iron oxide nanoparticle cross-linked catechol grafted polylysine (PLL)), arginine grafted biodegradable polymer (ABP), pegylated and PTX conjugated polymer micelles (APP), mPEG-b-Pip-CBA (PPCBA), PPCBA-PEI-arginine (PPA), polyethylene glycol (PEG), polylactide (PLA), polyglycolide (PGA), polyglycolic acid (PLGA), poly-ε-caprolactone (PCL), polyethyleneimine (PEI), hyaluronic acid (HA), gelatin, chitosan and serum albumin.
[0089] The PAPS polymer is PEI-Arg-mPEG-SS-mPEG-Arg-PEI and may have the structure of the following structural formula 1:
[0090] [Structural Formula 1]
[0091]
[0092] In Structural Formula 1, x and y may each independently be an integer of 1 to 500.
[0093] The PPSA polymer is mPEG-PEI-g-Arg-SS-Arg-g-PEI-mPEG and may have the structure of the following structural formula 2:
[0094] [Structural Formula 2]
[0095]
[0096] In Structural Formula 2, n and m may be an integer of 1 to 500, respectively and independently.
[0097] PICION is catechol-grafted polylysine (PLL) PEGylated and cross-linked with iron oxide nanoparticles, and may have the following structure, wherein catechol-grafted polylysine of the following structural formula 3 is cross-linked with iron oxide particles, and mPEG is modified on the surface thereof:
[0098] [Structural Formula 3]
[0099]
[0100] In Structural Formula 3, n may be an integer from 1 to 500.
[0101] The ABP polymer is an arginine-grafted biodegradable polymer (arginine-grafted bioreducible polymer), and may have the structure of the following Structural Formula 4:
[0102] [Structural Formula 4]
[0103]
[0104] In Structural Formula 4, n may be an integer from 1 to 500.
[0105] APP is a PEGylated and PTX-conjugated polymer micelle (PEGylated and PTX-conjugated polymer micelle, and may have the structure of the following structural formula 5:
[0106] [Structural Formula 5]
[0107]
[0108] In Structural Formula 5, n and m may be an integer of 1 to 500, respectively and independently.
[0109] The PPCBA polymer is mPEG-b-Pip-CBA, which is a pH-sensitive biodegradable polymer and may have the following structure of formula 6:
[0110] [Structural Formula 6]
[0111]
[0112] In Structural Formula 6, n and m may be an integer of 1 to 500, respectively and independently.
[0113] PPA is PPCBA-PEI-arginine, which is a pH-sensitive biodegradable polymer, and can be a polymer in which PEI and arginine are further combined with PPCBA. PPA can have the structure of the following structural formula 7:
[0114] [Structural Formula 7]
[0115]
[0116] In Structural Formula 7, a, b, and c may each independently be an integer of 1 to 500. For example, a may be 100 to 200, b may be 1 to 10, and c may be 1 to 5, or a may be 113, b may be 6, and c may be 1, but the present invention is not limited thereto.
[0117] Polyethyleneimine (PEI) may include all linear or branched polyethyleneimines to which the monomers of structural formula 8 are combined.
[0118] [Structural Formula 8]
[0119]
[0120] In Structural Formula 8, n may be an integer from 1 to 500.
[0121] The branched polyethyleneimine may include, in addition to the general branched polyethyleneimine, dendrimers in which molecular chains are regularly spread outward from the center in a three-dimensional manner according to certain rules.
[0122] [Structural Formula 9]
[0123]
[0124] An example of branched polyethyleneimine is shown in Structural Formula 9. Here, n may be an integer of 1 to 500.
[0125] The biodegradable polymer of the present invention includes a dendrimer polymer, which is an example of a polymer of structural formula 8 including vinylamine as a monomer. For example, the dendrimer-type branched polyethyleneimine may be a polymer of structural formula 10 or 11, but the present disclosure is not limited thereto. The polymer of structural formula 11 is a poly(amidoamine) polymer and may also be referred to as PAMAM.
[0126] [Structural Formula 10]
[0127]
[0128] [Structural Formula 11]
[0129]
[0130] The biocompatible polymer is combined with the recombinant adenovirus or viral DNA of the present invention to improve the efficiency of influx into cells, improve the stability of individuals, and increase the efficiency of delivery of the virus or viral DNA to the target site by reducing immunogenicity, thereby significantly improving the cancer therapeutic effect caused by the adenovirus or viral DNA of the present invention.
[0131] The biocompatible polymer and adenoviral system can be linked via electrostatic interactions, ionic interactions, or chemical bonds.
[0132] According to another aspect of the present invention, the present invention provides a pharmaceutical composition comprising a gene delivery system, the system comprising an interleukin 12 (IL-12) encoding nucleic acid sequence; and a nucleic acid sequence expressing an oligonucleotide that complementarily binds to the C-met gene and inhibits C-met expression. The composition can be an anti-cancer composition, an anti-metastatic composition for cancer cells, or a composition for enhancing anti-tumor immunity.
[0133] The composition may include a therapeutically effective amount of the adenovirus system of the present invention. In addition, the composition may also include a pharmaceutically acceptable carrier.
[0134] The anticancer composition is used to inhibit the survival, proliferation and / or migration of tumor cells, so as to inhibit the proliferation of cancer cells or induce or promote the death of cancer cells. The recombinant adenovirus system of the present invention or the composition comprising the same can effectively induce the death of cancer cells and inhibit their migration.
[0135] The anti-metastatic composition for cancer cells has the effect of inhibiting cancer cell migration by migration. For example, it can be confirmed that the anti-metastatic composition inhibits EMT in cancer cells, thereby inhibiting their migration. The anti-metastatic composition of the present invention can have an anti-cancer effect by killing cancer cells, and can have the effect of inhibiting cancer cell migration.
[0136] The composition for enhancing anti-tumor immunity is capable of treating cancer by overcoming immune surveillance avoidance of tumors using immunosuppressive molecules produced in tumor tissues, and can be included in the anti-cancer composition. Specifically, the anti-tumor immune composition is used to normalize the imbalance of immune cells in tumor tissues and induce the differentiation of T helper cells through IL-12, thereby activating the cytotoxicity of cytotoxic T lymphocytes and natural killer cells, thereby leading to enhanced anti-cancer immunity.
[0137] The pharmaceutical composition of the present invention expresses IL-12 to enhance the anti-cancer immunity of cancer subjects. In addition, the expression of C-met is inhibited by shRNA against C-met, thereby also amplifying the function of IL-12. In the embodiments of the present invention, it has been confirmed that even in a mouse model injected with human cancer cells, when the IL-12 and sh c-met co-expressing adenovirus of the present invention are injected, significant anti-cancer effects and tumor migration effects occur.
[0138] In addition, the composition can be a composition for adjuvant therapy to enhance the therapeutic effect of standard therapy, or can be a composition for adjuvant therapy to enhance or enhance the effect of standard therapeutic agents, including other anticancer agents, immune checkpoint inhibitors and immunotherapeutic agents, etc.
[0139] The anticancer composition of the present invention uses the recombinant adenovirus included in the aforementioned composition to enhance anti-tumor immunity. Therefore, the description of the same contents is omitted to avoid excessive complexity of this specification.
[0140] According to an embodiment of the present invention, the cancer can be selected from gastric cancer, lung cancer, non-small cell lung cancer, breast cancer, ovarian cancer, liver cancer, bronchial cancer, nasopharyngeal cancer, laryngeal cancer, pancreatic cancer, bladder cancer, colorectal cancer, colon cancer, cervical cancer, bone cancer, non-small cell bone cancer, blood cancer, skin cancer (melanoma, etc.), head and neck cancer, uterine cancer, rectal cancer, anal cancer, colon cancer, fallopian tube cancer, endometrial cancer, vaginal cancer, vulvar cancer, Hodgkin's disease, esophageal cancer, small intestine cancer, endocrine cancer, thyroid cancer, parathyroid cancer, adrenal cancer, soft tissue sarcoma, urethral cancer, penile cancer, prostate cancer, adenocarcinoma, chronic or acute leukemia, lymphocytic lymphoma, renal or ureteral cancer, renal cell carcinoma, renal pelvic cancer, polyploid cancer, salivary gland cancer, sarcoma cancer, pseudomyxoma, hepatoblastoma, testicular cancer, glioblastoma, cleft lip cancer, ovarian germ cell tumor, basal cell carcinoma, multiple myeloma, gallbladder cancer, choroidal melanoma, ampullary cancer, peritoneal cancer, adrenal cancer, tongue cancer, small cell carcinoma, pediatric lymphoma, neuroblastoma, duodenal cancer, ureteral cancer, astrocytoma, meningioma, kidney cancer, vulvar cancer, thymic cancer, central nervous system (CNS) tumor, primary central nervous system lymphoma, spinal cord tumor, brain stem glioma or pituitary adenoma, but the present invention is not limited thereto.
[0141] All aforementioned compositions of the present invention all include pharmaceutically acceptable carrier.The pharmaceutically acceptable carrier used in the present invention is the carrier used conventionally in preparation, and includes lactose, dextrose, sucrose, sorbitol, mannitol, starch, gum arabic, calcium phosphate, alginate, gelatin, calcium silicate, fine crystalline cellulose, polyvinyl pyrrolidone, cellulose, water, syrup, methylcellulose, methyl hydroxybenzoate, propyl hydroxybenzoate, talcum powder, magnesium stearate, mineral oil etc., but the present invention is not limited thereto.Except the above-mentioned components, pharmaceutical composition of the present invention can also include lubricant, wetting agent, sweetener, flavoring agent, emulsifier, suspending agent, preservative etc.Suitable pharmaceutically acceptable carrier and preparation are described in detail in Remington Pharmaceutical Science (the 19th edition, 1995).
[0142] The composition of the present invention can be administered orally or parenterally. Parenteral administration can be intratumoral injection, intravenous injection, intradermal injection, subcutaneous injection, intramuscular injection, intraperitoneal injection, intrathecal injection, intracardiac injection, intrathoracic injection, intraarterial injection, intraosseous injection, intraarticular injection, percutaneous administration, etc., preferably parenteral administration.
[0143] Additionally, the composition may be used for local or systemic administration.
[0144] According to an embodiment of the present invention, the anti-tumor immunity enhancing composition of the present invention is preferably directly administered into a tumor, thereby having an anti-tumor immunity enhancing effect.
[0145] The suitable dose of the composition of the present invention can be changed according to factors such as formulation, mode of administration, patient's age, body weight, sex, pathological condition and diet, administration time, route of administration, excretion rate and response sensitivity. The daily dose of the pharmaceutical composition of the present invention is, for example, 0.2 to 1,000 mg / kg. However, various related factors (such as the amount of target tissue cells to be differentiated and propagated, route of administration and patient's body weight, age and sex) can be considered to determine the actual dose of active ingredient. Therefore, dosage can be provided in any form without limiting the scope of the present invention.
[0146] According to another aspect of the present invention, the present invention provides the use of a gene delivery system as an anticancer agent, the system comprising an interleukin 12 (IL-12) encoding gene; and a gene expressing an oligonucleotide that complementarily binds to the C-met gene to inhibit C-met expression. The gene delivery system of the present invention co-expresses IL-12 and C-met inhibitory RNA, thereby inhibiting tumor migration, while also enhancing the anti-tumor immune effect of IL-12. The use of the gene delivery system of the present invention as an anticancer agent applies to the above description of the gene delivery system or pharmaceutical composition mutatis mutandis in detail to avoid repeated descriptions.
[0147] According to another aspect of the present invention, a method for treating cancer is provided, which comprises administering a gene delivery system comprising a gene encoding interleukin 12 (IL-12); and a gene expressing an oligonucleotide that complementarily binds to the C-met gene to inhibit C-met expression, or a pharmaceutical composition comprising the gene delivery system to a subject.
[0148] The gene delivery system of the present invention co-expresses IL-12 and C-met inhibitory RNA, thereby inhibiting tumor migration, while also enhancing the anti-tumor immune effect attributed to IL-12, thereby producing a synergistic effect in cancer treatment. The method of using the gene delivery system of the present invention as an anticancer agent for treatment applies to the above description of the gene delivery system or pharmaceutical composition mutatis mutandis in detail to avoid repeated description.
[0149] Hereinafter, the present invention will be described in more detail with reference to the following examples. It is obvious to those skilled in the art that the examples are only used to specifically explain the present invention, and therefore, the present invention is not intended to be limited to the examples.
[0150] Example
[0151] Experimental preparation and construction of recombinant vectors
[0152]
Preparation Example 1
[0153] As cell culture media, Dulbecco's modified Eagle's medium (DMEM; Kit, Grand Island, NY), Los Angeles Park Memorial Institute medium (RPMI; Kit) or minimal essential medium (MEM; Kit) containing 10% fetal bovine serum, L-glutamine (2 mmol / L), penicillin (100 IU / mL) and streptomycin (50 mg / mL) were used. HEK293 (human embryonic kidney cell line expressing adenovirus E1 site), H1975 (human non-small lung cancer cell line) and HaK (hamster renal carcinoma cell line) were purchased from the American Type Culture Collection (ATCC, Manassas, VA). HaP-T1 (hamster pancreatic carcinoma cell line) was provided by Dr. Masato Abei (University of Tsukuba, Ibaraki, Japan). All cell lines were cultured in a humidified atmosphere at 37°C and 5% CO2 and tested negative for mycoplasma using Hoeschst dye, cell culture, and PCR. E. coli (Escherichia coli) were cultured in Luria Bertani medium at 37°C.
[0154] [Preparation Example 1] Construction of an oncolytic adenovirus system expressing IL-12 and / or shc-met
[0155] Preparation Example 1-1. Construction of pDNA expressing human IL-12 and shc-met
[0156] To investigate the antitumor effect and antitumor immune response using Ad vectors, two oncolytic adenoviral plasmid DNAs (referred to as Ad pDNA or oAd pDNA) based on mT-Rd19-RGD recombination were constructed to express antitumor immune genes, human interleukin-12 (hIL-12) and / or short hairpin RNA (hereinafter referred to as “shc-met”) that complementarily binds to C-met to inhibit the expression of C-met, which plays an important role in cancer cell growth and differentiation ( Figure 1 ): (mT-Rd19-RGD and mT-Rd19-RGD / hIL-12 / shc-met).
[0157] [Table 2]
[0158]
[0159] Preparation Examples 1 to 2. Construction of polymer-viral DNA complexes expressing mouse-derived IL-12 and shc-met
[0160] In addition, based on HE5cT-Rd19-RGD, genes expressing mouse-derived IL-12p35 (sequence ID No. 7) and IL-12p40 (sequence ID No. 8) were inserted. In addition, shRNA was designed using the 4398th to 4422nd nucleotides of the mouse C-met gene of sequence ID No. 11 as the target sequence (sequence ID No. 15). A HE5cT-Rd19-RGD / scIL-12 / shc-met plasmid DNA was constructed that complementary binds to the C-MET gene and expresses shc-met that can inhibit the expression of the C-MET gene, which has the nucleotide sequence of sequence ID No. 14 inserted. The constructed HE5cT-Rd19-RGD / scIL-12 / shc-met plasmid DNA was mixed with a PPCBA-PEI-arginine (PPA) polymer to construct a pDNA / PPA polymer complex.
[0161] [Preparation Example 2] Construction of recombinant oncolytic adenovirus expressing IL-12 and / or shc-met
[0162] To investigate the antitumor effect and antitumor immune response induced by anticancer adenovirus co-expressing IL-12 and shc-met, an anticancer adenovirus ( Figure 4 , when the recombinant adenovirus includes human sequences, they are labeled as HscIL-12 and Hshc-met, respectively):
[0163] HE5cT-Rd19-RGD: Ad vector that does not contain the expressed gene
[0164] HE5cT-Rd19-RGD / scIL-12: Ad vector expressing only IL-12
[0165] HE5cT-Rd19-RGD / shc-met: Ad vector expressing shRNA targeting the C-Met gene
[0166] HE5cT-Rd19-RGD / scIL-12 / shc-met: Ad vector expressing shRNA targeting IL-12 and c-Met genes
[0167] More specifically, genes expressing human IL-12p35 (sequence ID No. 1) and IL-12p40 (sequence ID No. 2) were inserted into HE5cT-Rd19-RGD, respectively. In addition, shRNA of sequence ID No. 12 with nucleotides 1987 to 2007 of human C-met mRNA of sequence ID No. 10 as the target sequence (sequence ID No. 13) was inserted into the recombinant adenovirus vector.
[0168] In addition, in the same manner as above, each gene expressing mouse-derived IL-12p35 (SEQ ID No. 8) and IL-12p40 (SEQ ID No. 9) respectively and a shc-met expression sequence (SEQ ID No. 14) that uses the 4398th to 4422nd nucleotides of the mouse-derived C-MET gene of SEQ ID No. 11 as a target sequence (SEQ ID No. 15) and complementarily binds to the nucleotides to inhibit its expression were inserted to prepare an adenovirus vector that co-expresses IL-12 and shcmet.
[0169] [Preparation Example 3] Animal Model Establishment
[0170] 3-1. Human xenograft lung cancer tumor model
[0171] When nude mice purchased from Orient were 6 to 8 weeks old, human lung cancer cell line (H1975) was inoculated at 3 × 10 6 cells / 50 μL were injected subcutaneously into nude mice. Next, when the tumor size reached an average of 100 mm 3 When the anticancer adenovirus of Preparation Example 1 or 2 was administered thereto, its effect was confirmed.
[0172] 3-2. Mouse tumor model
[0173] For the experiments, C57BL6 (B16-F10 tumor model) mice were purchased from Daehan Biolink, and BALB / C (CT26 tumor model) mice were purchased from Orient. When the mice were 6 to 8 weeks old, mouse skin cancer cell line (B16-F10) or mouse gastric cancer cell line (CT26) were inoculated at 5×10 5 cells / 50 μL were subcutaneously injected into mice, and then when the size of the tumor reached an average of 100 mm3, the anticancer adenovirus of Preparation Example 1 or 2 was administered, and its effect was confirmed.
[0174] [Experimental Example 1] Confirmation of the expression of mIL-12 and hIL-12 in cells by Ad pDNA
[0175] In order to investigate the expression of human IL-12 (hIL-12) gene by Ad pDNA constructed according to Preparation Example 1, mT-Rd19-RGD and mT-Rd19-RGD / hIL-12 / shc-met Ad pDNA were reacted with liposomes at room temperature, and then 50% confluent 293A (human embryonic kidney cell line with good intracellular delivery efficiency) was reacted with the reaction product. 72 hours after treatment, the cell culture medium was collected to perform hIL-12 ELISA.
[0176] like Figure 2As shown, in the case of the example (mT-Rd19-RGD / hIL-12 / shc-met Ad pDNA; two Pac I), hIL-12 was confirmed to be expressed at 97,500±6,384 pg / mL. Therefore, it was confirmed that the Ad pDNA constructed according to the example effectively induced the expression of the therapeutic gene interleukin 12 in cells.
[0177] [Experimental Example 2] Confirmation of adenovirus (Ad) pDNA co-expression of intercellular IL-12 and C-met
[0178] The expression of hIL-12 by mT-Rd19-RGD / hIL-12 / shc-met Ad pDNA was investigated in the 293A cell line in consideration of the intracellular delivery efficiency of the adenoviral pDNA constructed according to Preparation Example 1. However, inhibition of C-met expression by expression of C-met-specific shRNA was not confirmed in the 293A cell line because C-met is not overexpressed in normal 293A cells.
[0179] Therefore, in order to verify the C-met expression inhibition ability of the exemplary mT-Rd19-RGD / hIL-12 / shc-met (two Pac I), mT-Rd19-RGD / hIL-12 / shc-met adenovirus (Ad) was prepared, and 50% confluent human lung cancer cell line A549 overexpressing C-met in a 6-well plate was treated with 20 μl of the prepared mT-Rd19-RGD / hIL-12 / shc-met adenovirus (Ad). 48 hours after treatment, the cell culture medium was collected and ELISA of hIL-12 and C-met was performed. The expression levels of hIL-12 and C-met in the untreated A549 human lung cancer cell line were used as controls.
[0180] like Figure 3 As shown, it was confirmed that the expression of hIL-12 (235,000±20,518 pg / mL) of mT-Rd19-RGD / hIL-12 / shc-met Ad was increased compared with the control, and the expression of C-met in the group treated with mT-Rd19-RGD / hIL-12 / shc-met Ad was reduced by 1.2 times. Therefore, it can be confirmed that the expression of therapeutic genes IL-12 and shc-met is effectively induced by the Ad system prepared according to the present invention.
[0181] [Experimental Example 3] Confirmation of the in vivo antitumor effect of anticancer adenovirus co-expressing IL-12 and shc-met (mouse syngeneic tumor model)
[0182] In order to verify the anti-cancer therapeutic effect of the anti-cancer adenovirus co-expressing mouse IL-12 and mouse C-met targeting shc-met constructed according to Preparation Example 2, the corresponding tumor models were established using the mouse skin cancer cell line B16-F10 or the mouse gastric cancer cell line CT26, and the anti-tumor effect was confirmed.
[0183] In 5x10 5 After subcutaneous injection of mouse skin cancer cell line B16-F10 or mouse gastric cancer cell line CT26 into mice, when the tumor size reached an average of 100 mm 3 At 2 dpi, PBS or HE5cT-Rd19-RGD / scIL-12 / shc-met were injected into mice. 10 After VP) was administered to the tumor three times, the size of the tumor was measured to observe the antitumor effect.
[0184] like Figure 5a and 5b As shown, it was confirmed that using two types of mouse tumor models, the tumors grew rapidly in the PBS-treated group, but completely disappeared in all subjects administered with HE5cT-Rd19-RGD / scIL-12 / shc-met.
[0185] [Experimental Example 4] Confirmation of the in vivo antitumor effect of the anticancer adenovirus pDNA / PPA complex co-expressing IL-12 and shc-met (mouse syngeneic tumor model)
[0186] A complex (pDNA / PPA) of HE5cT-Rd19-RGD / scIL-12 / shc-met viral DNA) and PPA polymer constructed according to Preparation Examples 1 to 2 was constructed to confirm the anticancer therapeutic effect. Specifically, a tumor model was established using the mouse skin cancer cell line B16-F10, and the antitumor effect thereof was confirmed. The mouse skin cancer cell line (B16-F10) was inoculated with 5×10 5 10 cells / 50 μL were injected subcutaneously into mice and then, when tumors reached an average size of 100 mm 3 At 14:1, PBS and HE5cT-Rd19-RGD / scIL-12 / shc-met Ad pDNA / PPA complex were injected into the mouse model. After seven daily administrations to the tumor, the size of the tumor was measured to observe the anti-tumor effect.
[0187] like Figure 6 As shown, it was confirmed that the size of the tumor in the PBS administration group increased to 2514.7±202.1 mm 3The mean tumor size in the group administered with HE5cT-Rd19-RGD / scIL-12 / shc-met Ad pDNA / PPA complex was 1387.6±171.8mm 3 , which was 44.8% lower than that of the PBS-administered group. This result indicates that viral DNA co-expressing IL-12 and shc-met also induced an enhanced anti-tumor effect.
[0188] [Experimental Example 5] Confirmation of intercellular expression of IL-12 and shc-met by anticancer adenovirus co-expressing IL-12 and shc-met (human)
[0189] To investigate the targeting of shc-Met by expressing human IL-12 or human c-Met via anticancer adenovirus co-expressing IL-12 and shc-Met, 247 cells were grown at an MOI of 2 ( Figure 7b ) or 5MOI( Figure 7a ) Each of the recombinant adenovirus HE5cT-Rd19-RGD, HE5cT-Rd19-RGD / shc-met, and HE5cT-Rd19-RGD / hscIL-12 / shc-met constructed according to Preparation Example 2 was administered to the human lung cancer cell line H1975. 48 hours after the treatment, the cells and the culture medium were collected to perform ELISA of human IL-12 and Western blotting of c-Met, and the expression of each gene was confirmed.
[0190] like Figure 7a As shown, it was confirmed that human IL-12 was expressed in the HE5cT-Rd19-RGD / hscIL-12 (3066.3±165.7 pg / mg) and HE5cT-Rd19-RGD / hscIL-12 / shc-met (94922.6±185.8 pg / mg) recombinant vectors.
[0191] In addition, if Figure 7b As shown, it was confirmed that the expression of C-met was inhibited in cells treated with HE5cT-Rd19-RGD / shc-met or HE5cT-Rd19-RGD / hscIL-12 / shc-met recombinant vectors compared with the HE5cT-Rd19-RGD control. Therefore, it was confirmed that the expression of therapeutic genes IL-12 and shc-met inserted into the recombinant anticancer adenoviral vector prepared in the present invention can be effectively induced.
[0192] [Experimental Example 6] Verification of the cancer cell killing ability of anticancer adenovirus co-expressing human IL-12 and shc-met
[0193] In order to investigate the cancer cell killing ability of anticancer adenovirus co-expressing human IL-12 and shc-met, the human lung cancer cell line H1975 was infected with anticancer adenovirus HE5cT-Rd19-RGD prepared according to Preparation Example 2; HE5cT-Rd19-RGD / hscIL-12; HE5cT-Rd19-RGD / shc-met; or HE5cT-Rd19-RGD / hscIL-12 / shc-met at an MOI of 2, 5, 10, 20 or 50, and the cancer cell killing ability of the adenovirus was observed under normoxic conditions (normoxia) and hypoxic conditions (hypoxia).
[0194] like Figure 8a and 8b As shown, it was confirmed that the cancer cell killing ability of HE5cT-Rd19-RGD, HE5cT-Rd19-RGD / hscIL-12, HE5cT-Rd19-RGD / shc-met or HE5cT-Rd19-RGD / hscIL-12 / shc-met was increased in proportion to the virus titer under normoxic and hypoxic conditions. In addition, under 50MOI infection conditions, the cancer cell killing ability of the group treated with a single therapeutic gene (ie, HE5cT-Rd19-RGD / hscIL-12 or HE5cT-Rd19-RGD / shc-met) was improved compared with HE5cT-Rd19-RGD, but the co-expression group (ie, HE5cT-Rd19-RGD / hscIL-12 / shc-met) induced a significantly improved cancer cell killing ability compared with the single treatment group. This result indicates that co-expression of IL-12 and shc-met exhibits a synergistic effect in chemotherapy.
[0195] [Experimental Example 7] Verify the ability of anticancer adenovirus co-expressing human IL-12 and shc-met to inhibit HUVEC migration and invasion
[0196] HGF expressed in cancer cells has been reported to increase cancer cell migration and invasion by activating the C-met signaling system in vascular endothelial cells, thereby inducing abnormal angiogenesis. Therefore, the following experiments were performed to confirm whether anticancer adenovirus co-expressing IL-12 and shc-met could reduce the metastatic and invasive ability of HUVECs.
[0197] Human lung cancer cell line H1975 has been infected with HE5cT-Rd19-RGD, HE5cT-Rd19-RGD / hscIL-12, HE5cT-Rd19-RGD / shc-met or HE5cT-Rd19-RGD / hscIL-12 / shc-met, and then the supernatant is collected to perform migration and invasion assays. As controls, untreated culture medium (fresh culture medium, 5% FBS RPMI) and cancer cell culture medium (H1975 culture medium, H1975-CM) without injection of anticancer virus were used.
[0198] like Figure 9a , 9b , 9c and 9d, it was confirmed that the migration and invasion ability of HUVEC in H1975-CM (cancer cell culture medium not infected with anticancer virus) was improved compared with the group treated with untreated culture medium (fresh culture medium). On the other hand, it was confirmed that in the cancer cell group treated with HE5cT-Rd19-RGD / HscIL-12 or HE5cT-Rd19-RGD / Hshc-met infected culture medium, the migration and invasion ability of HUVEC was reduced compared with the group infected with HE5cT-Rd19-RGD, specifically, in the cancer cell culture medium infected with HE5cT-Rd19-RGD / HscIL-12 / Hshc-met, the migration and invasion ability of HUVEC was significantly inhibited. These results indicate that the amount of HGF expressed in cancer cells is effectively inhibited by the anticancer adenovirus co-expressing IL-12 and shc-met, thereby producing a synergistic effect in reducing the migration and invasion ability of HUVEC.
[0199] [Experimental Example 8] Confirmation of the epithelial-mesenchymal mutation (Endo-MT) inhibitory effect of anticancer adenovirus co-expressing human IL-12 and shc-met
[0200] In order to verify the vascular normalization induced by anticancer adenovirus co-expressing IL-12, shc-met, and H1975, human lung cancer cell lines were infected with HE5cT-Rd19-RGD, HE5cT-Rd19-RGD / HscIL-12, HE5cT-Rd19-RGD / Hshc-met, or HE5cT-Rd19-RGD / HscIL-12 / Hshc-met, and then the supernatant was collected. HUVEC cells were cultured in the supernatant, and then the changes in the expression of endothelial or mesenchymal markers were investigated by Western blotting. As controls, untreated culture medium (fresh culture medium, 5% FBS RPMI) and culture medium of cancer cells not infected with anticancer viruses were used.
[0201] like Fig.10As shown, it was confirmed that in the case of a group treated with a culture medium collected from cancer cells infected with HE5cT-Rd19-RGD / Hshc-met or HE5cT-Rd19-RGD / HscIL-12 / Hshc-met, the expression of mesenchymal markers N-cadherin and a-SMA was reduced compared to the control (fresh culture medium treatment group). Among them, the group treated with adenovirus co-expressing IL-12 and shc-met showed the most excellent expression reduction effect. These results indicate that the co-expression of IL-12 and shc-met not only inhibits the migration and invasion ability of HUVEC cells, but also inhibits endo-MT conversion, thereby showing an excellent vascular renormalization effect.
[0202] [Experimental Example 9] Confirmation of the in vivo antitumor effect of anticancer adenovirus co-expressing IL-12 and shc-met in a human xenograft tumor model
[0203] In order to verify the anti-cancer therapeutic effect of the anti-cancer adenovirus of the present invention co-expressing IL-12 and shc-met in a human xenograft tumor model, a tumor model was established using the human lung cancer cell line H1975, and the anti-tumor effect therein was investigated.
[0204] To establish a human xenograft tumor model, specifically, 3x10 6 Human lung cancer cell line (H1975) was injected subcutaneously into nude mice, and then, when the tumor size reached an average of 100 mm 3 PBS, HE5cT-Rd19-RGD, HE5cT-Rd19-RGD / HscIL-12, HE5cT-Rd19-RGD / HscIL-met, and HE5cT-Rd19-RGD / Hshc-12 / Hshc-met were administered at 4 ℃ and 1 ℃ respectively. The tumors were dosed twice every two days (5x10 6 pfu), and the tumor size was measured.
[0205] like Fig.11As shown, it was confirmed that the tumor rapidly proliferated in the PBS administration group, but a significant antitumor effect was observed in all groups administered with anticancer adenovirus. Specifically, it was confirmed that the tumor size in HE5cT-Rd19-RGD was reduced by 81.7%, the tumor size in HE5cT-Rd19-RGD / HscIL-12 was reduced by 85.5%, the tumor size in HE5cT-Rd19-RGD / Hshc-met was reduced by 92.2%, and the tumor size in HE5cT-Rd19-RGD / HscIL-12 / Hshc-met was reduced by 94.6% compared with the PBS administration group. Through these results, it can be confirmed that when anticancer adenovirus co-expressing IL-12 and shc-met is used, a synergistic effect can be provided compared with a single treatment group.
[0206] [Experimental Example 10] Anticancer adenovirus co-expressing IL-12 and Lbcpf1-crMET confirmed the reduction of IL-12 expression and C-met expression in cells
[0207] [Experimental Example 10-1] Construction of anticancer adenovirus co-expressing IL-12 and C-met targeting CRISPR RNA
[0208] A CRISPR RNA system (LbCpf1-crRNA system) was constructed using 3.5 generation gene scissors (CRISPR / Cpf1), which can allow gene correction and desired mutations to occur during the process of cutting the target DNA, and then reconnect it through the intracellular repair system to investigate whether the same effect is exhibited when the CRISPR system is used in the adenovirus system of the present invention. The IL-12 sequence is located in the recombinant vector in the same manner as in Preparation Example 2, but the sequence (SEQ ID No. 6) of the IRES coding sequence (SEQ ID No. 20) is included (in Fig.12 The p35 coding sequence of IL-12 (indicated as HIL-12 in FIG. 4 ) is placed between the p35 coding sequence of IL-12 (SEQ ID NO: 4) and the p40 coding sequence of IL-12 (SEQ ID NO: 5).
[0209] The C-met target guide RNA sequence was selected using a program, and then oligomer synthesis was performed by biomimetic. Cloning was performed by renaturation. The Cpf1 protein coding gene (sequence ID No. 18) was inserted into the E1 site of the RdB-RGD adenovirus, and the U6 promoter was positioned upstream of the site expressing the guide RNA (crC-met). In addition, the IL-12 coding sequence; and the sequence expressing the C-met-targeting guide RNA (sequence ID No. 16) were inserted into the E3 region of the RdB-RGD adenovirus to construct a recombinant adenovirus that co-expresses IL-12 and the CRISPR-CAS system. The guide RNA was designed to target the 55th to 77th nucleotides of the human C-met sequence of sequence ID No. 10 ( Fig.12 ).
[0210] It has been confirmed that when the guide RNA (crcmet) expressed by the constructed recombinant adenovirus recognizes the target site of the target gene and specifies the position to be corrected, the gene scissors Cpf1 can cut the target site, thus effectively inhibiting C-met.
[0211] [Experimental Example 10-2] Investigation of the inhibitory effect of C-met due to anticancer adenovirus co-expressing IL-12 and C-met targeting CRISPR RNA
[0212] To investigate the expression of human IL-12 or the reduction of c-met expression through the Lbcpf1-crMET system due to anticancer adenovirus co-expressing IL-12 and Lbcpf1-crMET, the human lung cancer cell line H1975 was infected with anticancer adenovirus at 5 MOI or 100 MOI, and after 48 h, the cells and culture medium were collected and subjected to ELISA for human IL-12 ELISA or Western blotting for c-Met.
[0213] like Fig.13a , 13b As shown in Figures 13c and 13d, IL-12 expression of 9000.0±600.0pg / mL and 17400.0±1200.0pg / mL was confirmed in the groups treated with RdB-RGD / Lbcpf1 / HscIL-12 and RdB-RGD / Lbcpf1 / HscIL-12-crMET, respectively. In addition, it was confirmed that the expression of C-met was inhibited in all groups treated with anticancer viruses. Specifically, RdB-RGD / Lbcpf1 / HscIL-12-crMET most effectively reduced the expression of C-met.
[0214] [Experimental Example 11] Confirmation of the in vivo antitumor effect of anticancer adenovirus co-expressing IL-12 and Lbcpf1-crMET in a human xenograft tumor model
[0215] Experiments were performed to investigate whether inhibition of C-met expression by CRISPR rather than shRNA could be achieved together with expression of IL-12 in human xenograft tumor models.
[0216] The inhibition of C-met expression by CRISPR was investigated using the Lbcpf1-crMET system constructed according to Experimental Example 10-1.
[0217] In order to verify the anti-cancer therapeutic effect of anti-cancer adenovirus co-expressing IL-12 and Lbcpf1-crMET, a tumor model was established using the human lung cancer cell line H1975 and the anti-tumor effect was investigated. 6 Human lung cancer cell line H1975 was injected subcutaneously into nude mice, and then, when the tumor size reached an average of 90 mm 3 PBS, RdB-RGD / Lbcpf1, RdB-RGD / Lbcpf1 / HscIL, and RdB-RGD / Lbcpf1 / HscIL-12-crMET were administered at 4 ℃ and 1 ℃ respectively. The tumor was dosed three times (5x10 6 After VP), the tumor size was measured to observe the antitumor effect.
[0218] like Fig.14 As shown, in the PBS-administered group, the tumor size rapidly increased to 1486.5±221.1 mm on day 25. 3 , but significant antitumor effects were observed in all groups treated with anticancer viruses. The mean tumor size in the groups treated with anticancer viruses was 876.9±146.2 mm 3 (RdB-RGD / Lbcpf1), 792.0±230.3mm 3 (RdB-RGD / Lbcpf1 / scIL-12) and 535.6±172.6mm 3 (RdB-RGD / Lbcpf1 / scIL-12-crMET). That is, in the group treated with the anticancer virus, the size of the tumor was reduced by 41.0%, 46.7%, or 64% compared to the PBS administration group. Specifically, in the case of co-expression with IL-12 using the CRISPR method, the tumor size was significantly reduced. Therefore, it was confirmed that when the CRISPR system was used, a synergistic effect due to the two therapeutic genes was also exhibited. Sequence Listing <110> Gene Medicine Co., Ltd. <120> Antitumor composition <130> X19U10C0101 <150> 10-2018-0079752 <151> 2018-07-10 <160> 20 <170> PatentIn version 3.2 <210> 1 <211> 759 <212> DNA <213> Homo sapiens <400> 1 atgtggcccc ctgggtcagc ctcccagcca ccgccctcac ctgccgcggc cacaggtctg 60 catccagcgg ctcgccctgt gtccctgcag tgccggctca gcatgtgtcc agcgcgcagc 120 ctcctccttg tggctaccct ggtcctcctg gaccacctca gtttggccag aaacctcccc 180 gtggccactc cagacccagg aatgttccca tgccttcacc actcccaaaa cctgctgagg 240 gccgtcagca acatgctcca gaaggccaga caaactctag aatttaccc ttgcacttct 300 gaagagattg atcatgtaga tatcacaaaa gataaaacca gcacagtgga ggcctgttta 360 ccattggaat taaccaagaa tgagagttgc ctaaattcca gagagacctc tttcataact 420 aatgggagtt gcctggcctc cagaaagacc tcttttatga tggccctgtg ccttagtagt 480 attatgaag acttgaagat gtaccaggtg gagttcaaga ccatgaatgc aaagcttctg 540 atggatccta agaggcagat ctttctagat caaaacatgc tggcagttat tgatgagctg 600 atgcaggccc tgaatttcaa cagtgagact gtgccacaaa aatcctccct tgaagaaccg 660 gattttata aaactaaaat caagctctgc atacttcttc atgctttcag aattcgggca 720 gtgactattg atagagtgat gagctatctg aatgcttcc 759 <210> 2 <211> 921 <212> DNA <213> Homo sapiens <400> 2 atatgggaac tgaagaaaga tgttatgtc gtagaattgg attggtatcc ggatgcccct 60 ggagaaatgg tggtcctcac ctgtgacacc cctgaagaag atggtatcac ctggaccttg 120 gaccagagca gtgaggtctt aggctctggc aaaaccctga ccatccgagt caaagagttt 180 ggagatgctg gccagtacac ctgtcacaaa ggaggcgagg ttctaagcca ttcgctcctg 240 ctgcttcaca aaaaggaaga tggaatttgg tccactgata ttttaaagga ccagaaagaa 300 cccaaaaata agacctttct aagatgcgag gccaagaatt attctggacg tttcacctgc 360 tggtggctga cgacaatcag tactgatttg acattcagtg tcaaaagcag cagaggctct 420 tctgaccccc aaggggtgac gtgcggagct gctacactct ctgcagagag agtcagaggg 480 gacaacaagg agtatgagta ctcagtggag tgccaggagg acagtgcctg cccagctgct 540 gaggagagtc tgcccattga ggtcatggtg gatgccgttc acaagctcaa gtatgaaaac 600 tacaccagca gcttcttcat cagggacatc atcaaacctg acccacccaa gaacttgcag 660 ctgaagccat taaagaattc tcggcaggtg gaggtcagct gggagtaccc tgacacctgg 720 agtactccac attcctactt ctccctgaca ttctgcgtc aggtccaggg caagagcaag 780 agagaaaaga aagatagagt cttcacggac aagacctcag ccacggtcat ctgccgcaaa 840 aatgccagca ttagcgtgcg ggcccaggac cgctactata gctcatcttg gagcgaatgg 900 gcatctgtgc cctgcagtta g 921 <210> 3 <211> 1725 <212> DNA <213> Artificial <220> <223> Human IL-12 (p35-linker-p40 <400> 3 atgtggcccc ctgggtcagc ctcccagcca ccgccctcac ctgccgcggc cacaggtctg 60 catccagcgg ctcgccctgt gtccctgcag tgccggctca gcatgtgtcc agcgcgcagc 120 ctcctccttg tggctaccct ggtcctcctg gaccacctca gtttggccag aaacctcccc 180 gtggccactc cagacccagg aatgttccca tgccttcacc actcccaaaa cctgctgagg 240 gccgtcagca acatgctcca gaaggccaga caaactctag aattttaccc ttgcacttct 300 gaagagattg atcatgtaga tatcacaaaa gataaaacca gcacagtgga ggcctgttta 360 ccattggaat taaccaagaa tgagagttgc ctaaattcca gagagacctc tttcataact 420 aatgggagtt gcctggcctc cagaaagacc tcttttatga tggccctgtg ccttagtagt 480 atttatgaag acttgaagat gtaccaggtg gagttcaaga ccatgaatgc aaagcttctg 540 atggatccta agaggcagat ctttctagat caaaacatgc tggcagttat tgatgagctg 600 atgcaggccc tgaatttcaa cagtgagact gtgccacaaa aatcctccct tgaagaaccg 660 gatttttata aaactaaaat caagctctgc atacttcttc atgctttcag aattcgggca 720 gtgactattg atagagtgat gagctatctg aatgcttccg gtggcggtgg ctcgggcggt 780 ggtgggtcgg gtggcgggg atctatatgg gaactgaaga aagatgttta tgtcgtagaa 840 ttggattggt atccggatgc ccctggagaa atggtggtcc tcacctgtga cacccctgaa 900 gaagatggta tcacctggac cttggaccag agcagtgagg tcttaggctc tggcaaaacc 960 ctgaccatcc gagtcaaaga gtttggagat gctggccagt acacctgtca caaaggaggc 1020 gaggttctaa gccattcgct cctgctgctt caaaaaaagg aagatggaat ttggtccact 1080 gatattttaa aggaccagaa agaacccaaa aataagacct ttctaagatg cgaggccaag 1140 aattattctg gacgtttcac ctgctggtgg ctgacgacaa tcagtactga tttgacattc 1200 agtgtcaaaa gcagcagagg ctcttctgac ccccaagggg tgacgtgcgg agctgctaca 1260 ctctctgcag agagagtcag aggggacaac aaggagtatg agtactcagt ggagtgccag 1320 gaggacagtg cctgcccagc tgctgaggag agtctgccca ttgaggtcat ggtggatgcc 1380 gttcacaagc tcaagtga aaactacacc agcagcttct tcatcaggga catcatcaaa 1440 cctgacccac ccaagaactt gcagctgaag ccattaaaga attctcggca ggtggaggtc 1500 agctgggagt accctgacac ctggagtact ccacattcct acttctccct gacattctgc 1560 gttcaggtcc agggcaagag caagagagaa aagaaagata gagtcttcac ggacaagacc 1620 tcagccacgg tcatctgccg caaaaatgcc agcattagcg tgcgggccca ggaccgctac 1680 tatagctcat cttggagcga atgggcatct gtgccctgca gttag 1725 <210> 4 <211> 762 <212> DNA <213> Homo sapiens <400> 4 atgtggcccc ctgggtcagc ctcccagcca ccgccctcac ctgccgcggc cacaggtctg 60 catccagcgg ctcgccctgt gtccctgcag tgccggctca gcatgtgtcc agcgcgcagc 120 ctcctccttg tggctaccct ggtcctcctg gaccacctca gtttggccag aaacctcccc 180 gtggccactc cagacccagg aatgttccca tgccttcacc actcccaaaa cctgctgagg 240 gccgtcagca acatgctcca gaaggccaga caaactctag aatttaccc ttgcacttct 300 gaagagattg atcatgaaga tatcacaaaa gataaaacca gcacagtgga ggcctgttta 360 ccattggaat taaccaagaa tgagagttgc ctaaattcca gagagacctc tttcataact 420 aatgggagtt gcctggcctc cagaaagacc tcttttatga tggccctgtg ccttagtagt 480 attatgaag acttgaagat gtaccaggtg gagttcaaga ccatgaatgc aaagcttctg 540 atggatccta agaggcagat ctttctagat caaaacatgc tggcagttat tgatgagctg 600 atgcaggccc tgaatttcaa cagtgagact gtgccacaaa aatcctccct tgaagaaccg 660 gattttata aaactaaaat caagctctgc atacttcttc atgctttcag aattcgggca 720 gtgactattg atagagtgat gagctatctg aatgcttcct aa 762 <210> 5 <211> 987 <212> DNA <213> Homo sapiens <400> 5 atgtgtcacc agcagttggt catctcttgg ttttccctgg ttttctggc atctcccctc 60 gtggccatat gggaactgaa gaaagatgtt tatgtcgtag aattggattg gtatccggat 120 gcccctggag aaatggtggt cctcacctgt gacacccctg aagaagatgg tatcacctgg 180 accttggacc agagcagtga ggtcttaggc tctggcaaaa ccctgaccat ccaagtcaaa 240 gagtttggag atgctggcca gtacacctgt cacaaaggag gcgaggttct aagccattcg 300 ctcctgctgc ttcacaaaaa ggagatgga atttggtcca ctgatatttt aaaggaccag aaagaaccca aaataagac ctttctaaga tgcgaggcca agaattattc tggacgtttc 420 acctgctggt ggctgacgac aatcagtact gatttgacat tcagtgtcaa aagcagcaga ggctcttctg acccccaagg ggtgacgtgc ggagctgcta cactctctgc agagagagtc 540 agggggaca acaaggagta tgagtactca gtggagtgcc aggaggacag tgcctgccca gctgctgagg agagtctgcc cattgaggtc atggtggatg ccgttcacaa gctcaagtat 660 720. gaaaactaca ccagcagctt cttcatcagg gacatcatca aacctgaccc acccaagaac ttgcagctga agccattaaa gaattctcgg caggtggagg tcagctggga gtaccctgac acctggagta ctccacattc ctacttctcc ctgacattct gcgttcaggt ccagggcaag 840 agcaagagag aaaagaaga taggtcttc acggacaaga cctcagccac ggtcatctgc cgcaaaaatg cgcattag cgtgcgggcc cgcgct actatagctc atcttggagc gaatgggcat ctgtgccctg cagttag 987 <210> 6 <211> 2331 <212> DNA <213> Artificial <220> <223> Human IL-12 (p35-lRES-p40 <400> 6 atgtggcccc ctgggtcagc ctcccagcca ccgccctcac ctgccgcggc cacaggtctg 60 catccagcgg ctcgccctgt gtccctgcag tgccggctca gcatgtgtcc agcgcgcagc 120 ctcctccttg tggctaccct ggtcctcctg gaccacctca gtttggccag aaacctcccc 180 gtggccactc cagacccagg aatgttccca tgccttcacc actcccaaaa cctgctgagg 240 gccgtcagca acatgctcca gaaggccaga caaactctag aatttaccc ttgcacttct 300 gaagagattg atcatgaaga tatcacaaaa gataaaacca gcacagtgga ggcctgttta 360 ccattggaat taaccaagaa tgagagttgc ctaaattcca gagagacctc tttcataact 420 aatgggagtt gcctggcctc cagaaagacc tcttttatga tggccctgtg ccttagtagt 480 attatgaag acttgaagat gtaccaggtg gagttcaaga ccatgaatgc aaagcttctg 540 atggatccta agaggcagat ctttctagat caaaacatgc tggcagttat tgatgagctg 600 atgcaggccc tgaatttcaa cagtgagact gtgccacaaa aatcctccct tgaagaaccg 660 gattttata aaactaaaat caagctctgc atacttcttc atgctttcag aattcgggca 720 gtgactattg atagagtgat gagctatctg aatgcttcct aagccccccc ccctaacgtt 780 actggccgaa gccgcttgga ataaggccgg tgtgcgtttg tctatatgtt attttccacc 840 atattgccgt cttttggcaa tgtgagggcc cggaaacctg gccctgtctt cttgacgagc 900 attcctagct aggggtcttt cccctcgc caaaggaatg caaggtctgt tgaatgtcgt 960 gaaggaagca gttcctctgg aagcttcttg aagacaaaca acgtctgtag cgaccctttg 1020 caggcagcgg aaccccccac ctggcgacag gtgcctctgc ggccaaaagc cacgtgtata 1080 agatacacct gcaaaggcgg cacaacccca gtgccacgtt gtgagttgga tagttgtgga 1140 aagagtcaaa tggctctcct caagcgtatt caacaagggg ctgaaggatg cccagaaggt 1200 accccattgt atgggatctg atctggggcc tcggtgcaca tgctttacat gtgtttagtc 1260 gaggttaaaa aaacgtctag gcccccgaa ccacggggac gtggttttcc tttgaaaaac 1320 acgatgataa tatggccaca accaatgtgt caccagcagt tggtcatctc ttggttttcc 1380 ctggtttttc tggcatctcc cctcgtggcc atatgggaac tgaagaaaga tgtttatgtc 1440 gtagaattgg attggtatcc ggatgcccct ggagaaatgg tggtcctcac ctgtgacacc 1500 cctgaagaag atggtatcac ctggaccttg gaccagagca gtgaggtctt aggctctggc 1560 aaaaccctga ccatccaagt caaagagttt ggagatgctg gccagtacac ctgtcacaaa 1620 ggaggcgagg ttctaagcca ttcgctcctg ctgcttcaca aaaaggaaga tggaatttgg 1680 tccactgata ttttaaaagga ccagaaagaa cccaaaaaata agacctttct aagatgcgag 1740 gccaagaatt attctggacg tttcacctgc tggtggctga cgacaatcag tactgatttg 1800 acattcagtg tcaaaagcag cagaggctct tctgaccccc aaggggtgac gtgcggagct 1860 gctacactct ctgcagagag agtcagaggg gacaacaagg agtatgagta ctcagtggag 1920 tgccaggagg acagtgcctg cccagctgct gaggagagtc tgcccattga ggtcatggtg 1980 gatgccgttc acaagctcaa gtatgaaaac tacaccagca gcttcttcat cagggacatc 2040 atcaaacctg acccacca gaacttgcag ctgaagccat taagaattc tcggcaggtg 2100 gaggtcagct gggagtaccc tgacacctgg agtactccac attcctactt ctccctgaca 2160 ttctgcgttc aggtccagggg cttcacggac 2220 aagacctcag ccacggtcat ctgccgcaaa atgccagca ttagcgtgcg ggcccaggac 2280 cgctactata gctcatcttg gagcgaatgg gcatctgtgc cctgcagtta g 2331 <210> 7 <211> 645 <212> DNA <213> Muscles <400> 7 atgtgtcaat cacgctacct cctttttg gccaccttg ccctcctaaa ccctcagt 60 ttggccaggg tcattcagt ctctgacct gccaggtgtc tagccaggtc ccgaaacctg 120 ctgaagacca cagatgacat ggtgaagacg gccagagaaa aactgaaca ttattcctgc 180 actgctgaag acatcgatca tgagacacc acacgggacc aaaccagcac attgaagacc 240 tgtttaccac tggaactaca caagaacgag agttgcctgg ctactagaga gactctctcc 300 acaacagag ggagctgcct gccccacag aagacgctt tgatgatgac cctgtgcctt 360 ggtagcatct atgaggactt gaagatgtac cagacagagt tccaggccat caacgcagca 420 cttcagaatc acaaccatca gcagatcatt ctagacaagg gcatgctggt ggccatcgat 480 gagctgatgc agtctctgaa tcataatggc gagactctgc gccagaaacc tcctgtggga 540 gaagcagacc cttacagagt gaaaatgaag ctctgcatcc tgcttcacgc cttcagcacc 600 cgcgtcgtga ccatcaacag ggtgatgggc tatctgagct ccgcc 645 <210> 8 <211> 1005 <212> DNA <213> Mus musculus <400> 8 tgtcctcaga agctaaccat ctcctggttt gccatcgttt tgctggtgtc tccactcatg 60 gccatgtggg agctggagaa agacgtttat gttgtagagg tggactggac tcccgatgcc 120 cctggagaaa cagtgaacct cacctgtgac acgcctgaag aagatgacat cacctggacc 180 tcagaccaga gacatggagt cataggctct ggaaagaccc tgaccatcac tgtcaaagag 240 tttctagatg ctggccagta cacctgccac aaaggaggcg agactctgag ccactcacat 300 ctgctgctcc acaagaagga aaatggaatt tggtccactg aaattttaaa aaatttcaaa 360 aacaagactt tcctgaagtg tgaagcacca aattactccg gacggttcac gtgctcatgg 420 ctggtgcaaa gaaacatgga cttgaagttc aacatcaaga gcagtagcag ttcccctgac 480 tctcgggcag tgacatgtgg aatggcgtct ctgtctgcag agaggtcac actggaccaa 540 agggactatg agaagtattc agtgtcctgc caggagatg tcacctgccc aactgccgag 600 gagaccctgc ccattgaact ggcgttggaa gcacggcagc agaataata tgagaactac 660 agcaccagct tcttcatcag ggacatcatc aaaccagacc cgcccagaa cttgcagatg 720 aagcctttga agaaccaca ggtggaggtc agctgggagt accctgactc ctggagcact 780 ccccattcct acttctccct caagttctt gttcgaatcc agcgcaagaa agaaagatg 840 aaggagacag aggaggggtg taaccagaaa ggtgcgttcc tcgtagagaa gatactacc 900 gaagtccaat gcaaggcgg gatgtctgc gtgcaagctc aggatcgcta ttacaattcc 960 tcatgcagca agtgggcatg tgttccctgc agggtccgat cctag 1005 <210> 9 <211> 1695 <212> DNA <213> Artificial <220> <223> Mouse IL-12 (p35-linker-p40) <400> 9 atgtgtcaat cacgctacct cctctttttg gccacccttg ccctcctaaa ccacctcagt 60 ttggccaggg tcattccagt ctctggacct gccaggtgtc ttagccagtc ccgaaacctg 120 ctgaagacca cagatgacat ggtgaagacg gccagagaaa aactgaaaca ttattcctgc 180 actgctgaag acatcgatca tgaagacatc acacgggacc aaaccagcac attgaagacc 240 tgtttaccac tggaactaca caagaacgag agttgcctgg ctactagaga gacttcttcc 300 acaacaagag ggagctgcct gcccccacag aagacgtctt tgatgatgac cctgtgcctt 360 ggtagcatct atgaggactt gaagatgtac cagacagagt tccaggccat caacgcagca 420 cttcagaatc acaaccatca gcagatcatt ctagacaagg gcatgctggt ggccatcgat 480 gagctgatgc agtctctgaa tcataatggc gagactctgc gccagaaacc tcctgtggga 540 gaagcagacc cttacagagt gaaaatgaag ctctgcatcc tgcttcacgc cttcagcacc 600 cgcgtcgtga ccatcaacag ggtgatgggc tatctgagct ccgccggtgg cggtggctcg 660 ggcggtggtg ggtcgggtgg cggcggatct tgtcctcaga agctaaccat ctcctggttt 720 gccatcgttt tgctggtgtc tccactcatg gccatgtggg agctggagaa agacgtttat 780 gttgtagagg tggactggac tcccgatgcc cctggagaaa cagtgaacct cacctgtgac 840 acgcctgaag aagatgacat cacctggacc tcagaccaga gacatggagt cataggctct 900 ggaaagaccc tgaccatcac tgtcaaagag tttctagatg ctggccagta cacctgccac 960 aaaggaggcg agactctgag ccactcacat ctgctgctcc acaagaagga aaatggaatt 1020 tggtccactg aaattttaaa aaatttcaaa aacaagactt tcctgaagtg tgaagcacca 1080 aattactccg gacggttcac gtgctcatgg ctggtgcaaa gaaacatgga cttgaagttc 1140 aacatcaaga gcagtagcag ttcccctgac tctcgggcag tgacatgtgg aatggcgtct 1200 ctgtctgcag agaaggtcac actggaccaa agggactatg agaagtattc agtgtcctgc 1260 caggaggatg tcacctgccc aactgccgag gagaccctgc ccattgaact ggcgttggaa 1320 gcacggcagc agaataaata tgagaactac agcaccagct tcttcatcag ggacatcatc 1380 aaaccagacc cgcccaagaa cttgcagatg aagcctttga agaactcaca ggtggaggtc agctgggagt accctgactc ctggagcact ccccattcct acttctccct caagttcttt gttcgaatcc agcgcaagaa agaaaagatg aaggagacag aggaggggtg taaccagaaa ggtgcgttcc tcgtagaga gacatctacc gagtccat gcaaaggcgg gatgtctgc gtgcaagctc aggatcgcta ttacaattcc tcatgcagca agtgggcatg tgttccctgc 1680. agggtccgat cctag 1695 <210> 10 <211> 4227 <212> DNA <213> Homo sapiens <400> 10 atgaaggccc ccgctgtgct tgcacctggc atcctcgtgc tcctgtttac cttggtgcag aggagcaatg gggagtgtaa agggcacta gcaaagtccg agatgaatgt gaatatgaag 180. tatcagcttc ccaacttcac cgcggaaaca cccatccaga atgtcattct acatgagcat cacattttcc ttggtgccac tactacatt tatgttttaa atgaggaaga ccttcagaag gttgctgagt acaagactgg gcctgtgctg gaacacccag attgtttccc atgtcaggac 300 tgcagcagca aagccaattt atcaggaggt gtttggaag atacatcaa catggctcta 360 gttgtcgaca cctactatga tgatcactc attagctgtg gcagcgtca cagagggacc 420 tgccagcgac atgtctttcc ccacaatcat actgctgaca tacagtcgga ggttcactgc 480 atattctccc cacagataga agagcccagc cagtgtccctg actgtgtgt gagcgccctg 540 ggagccaaag tccttcatc tgtaaggac cggttcatca acttctttgt aggcaatacc 600 aaatttctt cttattccc agatcatcca ttgcattcga tatcagtg aaggctaaag 660 gaaacgaaag atggttttat gttttgacg gaccagtcct acatgatgt tttacctgag 720 ttcagagatt cttaccccat taagtatgtc catgcctttg aaagcaacaa ttttattac 780 ttcttgacgg tccaaggga aactctagat gctcagactt ttcacacag addaatcagg 840 ttctgttcca taaactctgg attgcattcc tacatggaaa tgctctgga gtgtattctc 900 acagaaaaga gaaaaagag atccacaag aaggaagtgt tattatact tcaggctgcg 960 tatgtcagca agcctggggc ccagcttgct agacaaatag gagccagcct gatgatgac 1020 attctttcg gggtgttcgc acaaagcaag ccagattctg ccgaaccaat ggatcgatct 1080 gccatgtgtg cattccctat caaatatgtc aacgacttct tcaacaagat cgtcaacaaa 1140 aacaatgtga gatgtctcca gcatttttac ggacccaatc atgagcactg ctttaatagg 1200 acacttctga gaaattcatc aggctgtgaa gcgcgccgtg atgaatatcg aacagagttt 1260 accacagctt tgcagcgcgt tgacttattc atgggtcaat tcagcgaagt cctcttaaca 1320 tctatatcca ccttcattaa aggagacctc accatagcta atcttgggac atcagagggt 1380 cgcttcatgc aggttgtggt ttctcgatca ggaccatcaa cccctcatgt gaatttctc 1440 ctggactccc atccagtgtc tccagaagtg attgtggagc atacattaaa ccaaaatggc 1500 tacacactgg tttcactgg gaagaagatc acgaagatcc cattgaatgg cttgggctgc 1560 agacatttcc agtcctgcag tcaatgcctc tctgccccac cctttgttca gtgtggctgg 1620 tgccacgaca aatgtgtgcg atcggaggaa tgcctgagcg ggacatggac tcaacagatc 1680 tgtctgcctg caatctacaa ggttttccca aatagtgcac cccttgaagg agggacaagg 1740 ctgaccatat gtggctggga ctttggattt cggaggaata ataaatttga tttaaagaaa 1800 actagagttc tccttggaaa tgagagctgc accttgactt taagtgagag cacgatgaat 1860 acattgaaat gcacagttgg tcctgccatg aataagcatt tcaatatgtc cataattatt 1920 tcaaatggcc acgggacaac acaatacagt acattctcct atgtggatcc tgtaataaca 1980 agtatttcgc cgaaatacgg tcctatggct ggtggcactt tacttacttt aactggaaat 2040 tacctaaaca gtgggaattc tagacacatt tcaattggtg gaaaaacatg tactttaaaa 2100 agtgtgtcaa acagtattct tgaatgttat accccagccc aaaccatttc aactgagttt 2160 gctgttaaat tgaaaattga cttagccaac cgagagacaa gcatcttcag ttaccgtgaa 2220 gatcccattg tctatgaaat tcatccaacc aaatctttta ttagtacttg gtggaaagaa 2280 cctctcaaca ttgtcagttt tctattttgc tttgccagtg gtgggagcac aataacaggt 2340 gttgggaaaa acctgaattc agttagtgtc ccgagaatgg tcataaatgt gcatgaagca 2400 ggaaggaact ttacagtggc atgtcaacat cgctctaatt cagagataat ctgttgtacc 2460 actccttccc tgcaacagct gaatctgcaa ctccccctga aaaccaaagc cttttcatg 2520 ttagatggga tcctttccaa atactttgat ctcatttatg tacataatcc tgtgtttaag 2580 ccttttgaaa agccagtgat gatctcaatg ggcaatgaaa atgtactgga aattaaggga 2640 aatgatattg accctgaagc agttaaaggt gaagtgttaa aagttggaaa taagagctgt 2700 gagaatatac acttacattc tgaagccgtt ttatgcacgg tccccaatga cctgctgaaa 2760 ttgaacagcg agctaaatat agagtggaag caagcaattt cttcaaccgt ccttggaaaa 2820 gtaatagttc aaccagatca gaatttcaca ggattgattg ctggtgttgt ctcaatatca 2880 acagcactgt tattactact tgggttttc ctgtggctga aaaagagaaa gcaaattaaa 2940 gatctgggca gtgaattagt tcgctacgat gcaagagtac acactcctca tttggatagg 3000 cttgtaagtg cccgaagtgt aagcccaact acagaaatgg tttcaaatga atctgtagac 3060 taccgagcta cttttccaga agatcagttt cttaattcat ctcagaacgg ttcatgccga 3120 caagtgcagt atcctctgac agacatgtcc cccatcctaa ctagtgggga ctctgatata 3180 tccagtccat tactgcaaaa tactgtccac attgacctca gtgctctaaa tccagagctg 3240 gtccaggcag tgcagcatgt agtgattggg cccagtagcc tgattgtgca tttcaatgaa 3300 gtcataggaa gagggcattt tggttgtgta tatcatggga ctttgttgga caatgatggc 3360 aagaaaattc actgtgctgt gaaatccttg aacagaatca ctgacatagg agaagtttcc 3420 caatttctga ccgagggaat catcatgaaa gattttagtc atcccaatgt cctctcgctc 3480 ctgggaatct gcctgcgaag tgaagggtct ccgctggtgg tcctaccata catgaaacat 3540 ggagatcttc gaaatttcat tcgaaatgag actcataatc caactgtaaa agatcttatt 3600 ggctttggtc ttcaagtagc caaagcgatg aaatatcttg caagcaaaaa gtttgtccac 3660 agagacttgg ctgcaagaaa ctgtatgctg gatgaaaaat tcacagtcaa ggttgctgat 3720 tttggtcttg ccagagacat gtatgataaa gaatactata gtgtacacaa caaaacaggt 3780 gcaaagctgc cagtgaagtg gatggctttg gaaagtctgc aaactcaaaa gtttaccacc 3840 aagtcagatg tgtggtcctt tggcgtcgtc ctctgggagc tgatgacaag aggagcccca 3900 ccttatcctg acgtaacac ctttgatata actgtttact tgttgcaagg gagaagactc ctacaacccg aatactgccc agacccctta tatgaagtaa tgctaaaatg ctggcaccct aaagccgaaa tgcgcccatc cttttctga ctggtgtccc ggatatcagc gatcttctct actttcattg gggagcacta tgtccatgtg aacgctactt atgtgaacgt aaaatgtgtc gctccgtatc cttctctgtt gtcatcagaa gataacgctg atgatgaggt ggacacacga ccagcctcct tctgggagac atcatag 4227 <210> 11 <211> 6652 <212> DNA <213> Mus musculus <400> 11 gctcggcggg gttcggcccg ggccgcaggt gacccggacg gcctcgccgc ccgcagcgtc cgagcccggg tgaccctgtg cggagccaga tgctgggcga ccgctgactc gctggagag 120 ggcggagcgc gcgggtggtc cccagccggc tgacttcggc gccgcgcgct ccggggcaccc 180 240. caaggtacaa actccagccg cgtcgatcag gcacccagcc tctcccagcc cctctgcttt ctttgttcca ctaaggac tggctactgc tctggaggac aagaccaccg aggatggctg tggagagaaa gctgacggtg tagcagaacg cttggcatgt gatcaactcc tcacaatgaa 360 ggctcccacc gtgctggcac ctggcattct ggtgctgctg ttgtccttgg tgcagaggag 420 ccatggggag tgcaaggagg ccctagtgaa gtctgagatg aacgtgaaca tgaagtatca 480 gctccccaac ttcacggcag aaacccccat ccagaatgtc gtcctacacg gccatcatat 540 ttatctcgga gccacaaact acatttatgt tttaaatgac aaagaccttc agaaggtatc 600 cgaattcaag accgggcccg tgttggaaca cccagattgt ttaccttgtc gggactgcag 660 cagcaaagcc aattcatcag gaggggtttg gaaagacaac atcaacatgg ctctgcttgt 720 tgacacatac tatgatgatc aactcattag ctgtggcagt gtcaacagag ggacttgcca 780 gcggcatgtc cttcctcctg acaattctgc tgacatccag tctgaggtcc actgcatgtt 840 ctccccagaa gaggagtcag ggcagtgtcc tgactgtgta gtgagtgccc tcggagccaa 900 agtcctcctg tcggaaaagg accggttcat caatttcttt gtggggaata cgatcaattc 960 ctcctatcct cctggttatt cactgcattc gatatcggtg agacggctga aggaaaccca 1020 agatggtttt aagtttttga cagaccagtc ctatattgat gtcttaccag aattccaaga 1080 ttcctacccc ataaagtaca tacatgcctt cgaaagcaac cattttattt actttctgac 1140 tgtccaaaag gaaactctag atgctcagac ttttcataca agaataatca ggttctgttc 1200 cgtagactct gggttgcact cctacatgga aatgcccctg gaatgcatcc tgacagaaaa 1260 aagaaggaag agatccacaa gggaagaagt gtttaatatc ctccaagccg cgtatgtcag 1320 taaaccaggg gccaatcttg ctaagcaaat aggagctagc ccttctgatg acattctctt 1380 cggggtgttt gcacaaagca agccagattc tgctgaacct gtgaatcgat cagcagtctg 1440 tgcattcccc atcaaatatg tcaatgactt cttcaacaag attgtcaaca aaaacaacgt 1500 gagatgtctc cagcattttt acggacccaa ccatgagcac tgtttcaata ggaccctgct 1560 gagaaactct tccggctgtg aagcgcgcag tgacgagtat cggacagagt ttaccacggc 1620 tttgcagcgc gtcgacttat tcatgggccg gcttaaccaa gtgctcctga catccatctc 1680 caccttcatc aaaggtgacc tcaccattgc taatctaggg acgtcagaag gtcgcttcat 1740 gcaggtgtg ctctctcgaa cagcacacct cactctcat gtgaacttcc tcctggactc 1800 ccatcctgta tctccagaag ttattgttga gcatccatca atcaaatg gctatacatt 1860 ggttgtcaca ggaaagaga tcaccagat tccattgaat ggctgggct gtggacattt 1920 ccaatcctgc agtcagtgcc tctctgcccc ttacttata cagtgtggct ggtgccacaa 1980 tcaatgtgtg cgttttgatg aatgccccag cggtacatgg actcaagaga tctgtctgcc 2040 ggcggtttat aaggtgttcc ccaccagcgc gccccttgaa ggaggaacag tgttgaccat 2100 atgtggctgg gactttggat tcaggagaa taataattt gatttaagga aaaccaaagt 2160 tctgcttggc aacgagagct gtaccttgac cttaagcgag agcacgacaa atacgttgaa 2220 atgcacagtt gtcccgcga tgagtgagca cttcaatgtg tctgtatatta tctcaacag 2280 tcgagagacg acgcaataca gtgcattctc ctagtagat cctgtataataa caagcattc 2340 tccgaggtac ggccctcagg ctggaggcac cttactcact cttactggga atacctca 2400 cagtggcaat tcgacaca ttcaatttgg agggaaaaca tgtactttaa aaagtgtatc 2460 agatagtatt cttgaatgct acaccccagc ccaaactacc tctgatgagt ttcctgtgaa 2520 attgaagatt gacttggcta accgagagac cagcagcttc agttaccggg aagaccccgt 2580 tgtctatgaa atccacccga ccaaatcttt tattagtggt ggaagcacaa taacgggtat 2640 tgggaagacc ctgaactcgg ttagcctccc aaagctggta atagatgtgc atgaagtggg 2700 tgtgaactac acagtggcat gtcagcatcg ctcaaattca gagatcatct gctgcactac 2760 tccttcactg aaacagctgg gcctgcaact ccccctgaag accaaagcct tcttcctgtt 2820 agacgggatt ctttccaaac actttgatct cacttatgtg cataatcctg tgtttgagcc 2880 ttttgaaaag ccagtaatga tctcaatagg caatgaaaat gtagtggaaa ttaagggaaa 2940 caatattgac cctgaagcag ttaaaggtga agtgttaaaa gttggaaatc agagctgcga 3000 gagtctccac tggcactctg gagctgtgtt gtgtacagtc cccagtgacc tgctcaaact 3060 gaacagcgag ctaaatatag agtggaagca agcagtctct tcaactgttc ttggaaaagt 3120 gatcgttcaa ccggatcaga atttgcagg attgatcatt ggtgcggtct caatatcagt 3180 agtagttttg ttattatccg ggctcttcct gtggatgaga aagagaaagc ataaagatct gggcagtgaa ttagttcgct atgacgcaag agtacacact cctcatttgg atggcttgt aagtgcccga agtgtaagtc caactacaga gatggtttca aatgagtctg tagactacag agctactttt ccagaagacc agttttcccaa ctcctctcag aatggagcat gcagacaagt gcaataccct ctgacagacc tgtcccctat cctgacaagt ggagactctg atatatccag cccattacta caaaatactg ttcacattga cctcagtgct ctaaatccag agctggtcca agcagttcag cacgtagtga ttggacccag cagcctgatt gtgcatttca atgaagtcat aggaagaggg cattttggct gtgtctatca tgggactttg ctggacaatg acggaaaga aattcactgt gctgtgaat ccttaatag aatcacagat aatgaagg tctcccagtt tctgactgag ggaatcatca tgaaagactt cagccatccc aatgttctct cactcttggg aatctgcctg ggtctcctct ggtggtcctg ccctatatga 3840 tctgcgaaat ttcattcgaa acgagactca taatccaact gtgaaagatc ttataggatt tggccttcaa gtagccaaag gcatgaaata tcttgccagc aaaaagtttg tccacagaga 3960 cttagctgca agaaactgca tgttggatga aaaattcact gtcaaggttg ctgatttcgg 4020 tcttgccaga gacatgtacg ataaagagta ctatagtgtc cacaacaaga cgggtgccaa 4080 gctaccagta aagtggatgg ctttagagag tctgcaaacg cagaagttca ccaccaagtc 4140 agatgtgtgg tcctttggtg tgctcctctg ggagctcatg acgagaggag cccctcctta 4200 tcccgacgtg aacacatttg atatcactat ctacctgttg caaggcagaa gactcttgca 4260 accagaatac tgtccagacg ccttgtacga agtgatgcta aaatgctggc accccaaagc 4320 ggaaatgcgc ccgtcctttt ccgaactggt ctccaggata tcctcaatct tctccacgtt 4380 cattggggaa cactacgtcc acgtgaacgc tacttatgtg aatgtaaaat gtgttgctcc 4440 atatccttct ctgttgccat cccaagacaa cattgatggc gaggggaaca catgatgaat 4500 gagaggtcca ccagcccact tccaagaaac agttctggcc caaaccagac tatcccttcc 4560 ccaacagttc tcactgcctg gcctttggaa ggtcacttaa catttgttgt tgttttgttt 4620 tgttttttgt ttgctttg cggtaactgc accactatga aacattgact tgctatttca 4680 aattcctgga ttctaaggaa tttctcatct gacaatggaa cagaaataga agcatggccc 4740 ccacaggctg gggaccagtg gcaacctgca gctacaacac tcctatctca gcggaattct 4800 aaatctcagt tctggcttaa aagttttaaa aataagatat atatacatat atatatccaa 4860 tacaatgaac tttgaagatt tctcagaaaa ctcagaagaa acgccctctt tcaggataaa 4920 tgtggtgttc ctagcaggct gcttgttgaa attccagtgt tttaaaaata tttttgttgt 4980 gttgcagtcg tgaacatttt ccatttctga tgttgtctgc ccatcaggca aacattccct 5040 tttaaatgct tatatacaca ttccttaggt tggaagaata tccacggaca atgcacttat 5100 ttttaaacga gcatgacatg aggtgtgttt ataaattatc agggatttta tgtattgtac 5160 atagatgaca ataggaaatt gtttatttca agaaatagct ttgttacagt aaaatatttg 5220 tcatttaaaa cccagctgtt tagcaaggag tgttggctca cacctacaat cccagcattt 5280 gggaagctga ggcaagcaga ttaccacaag tttgaaacca accttggctg catacagatg 5340 atgtatatat aggccagcat gggttacact gtctgtctta gcaaacaaaa tttcaactgt 5400 ttgagaaaga ttttgttctg atctaatgaa tgtggacatt taaattttt atctgttttt 5460 taatggcaac tttggaaata agtaacttgc ggtgataaat ctttttaaag gcaactcagt 5520 atttttaaa ggacaaaata aactgactga agggttcgct acttccagtc acaacctgtg 5580 tatagaagaa agaaagggtc agtgatcgag aatcagacac tctcgttcag gaggaggctt 5640 ctcgcctgaa acaattgcac ccaacacttt tggggaagtc tcatttttgc attaggacat 5700 attttaggtt aaacaaaagc atattttaga aacagacaaa agccaactga aaatcgtgga 5760 tgaatagtta ctctggacag gacttttgac atgtcttgct ctgtggaatt ttgtgcttac 5820 tactgtatag tgcatgtggc ttaggttacc ctagctggtt ttgtccgtgt aaacattgaa 5880 agtattat ttttatagaa atgtttatt ttaatgatgt aagaaaaatt ttccttaggc 5940 cgcagaaatc ctgcactgtg agcatttcag aagaggtatg tgagacccag ttcaacgaca 6000 gcatgatttt ttaaatggct gtaagttatg ataaggaaat gtactgattg ccagtgcact 6060 ccaccctcat tacgtcacca ggacttgaag ccaagggtta agagggcaag ctatgacatg 6120 ggtgtgtggt ctgctgaaac ccaatcgttg aacttggctg ttgttacagg aaaatgatgg 6180 catcaacagg tctttgatgg tggtggagca tatcagaaca cataaggaac tgtagcccag 6240 atttattca attcaaatat tactgcttcg taattatgaa gagtagtgca aatttacaga 6300 gcactgtcaa agactgacag aaaaaaaaa gatctgctct gtagaaagaa ttgtctgcca 6360 ttacagggtc aagaaaatga atgcgccaat aacagtaaga gctgtggaag acacccatac 6420 ctgtatatac atgctcgaga aagctgtaat gtgaaaatca tgttctctat ttatgactct 6480 tcctagggca atgtgtctgg acagattgta agagtaagtc atttcctaa agaattagat 6540 atttgtcact gcctatacct gcagttgagc tgaatggtac tccatgtgtt aataattgtt 6600 ctgatgaatc atacagttga aataaagtga cgtaacatct tgtatactgt ga 6652 <210> 12 <211> 62 <212> DNA <213> Artificial <220> <223> shRNA SEQ. for Human c-met <400> 12 caaactagag ttctccttgg aattcaagag attccaagga gaactctagt ttttttttgg 60 aa 62 <210> 13 <211> 21 <212> DNA <213> Artificial <220> <223> Target sequence in Human c-met <400> 13 aaactagagt tctccttgga a 21 <210> 14 <211> 69 <212> DNA <213> Artificial <220> <223> shRNA SEQ for Mouse c-met <400> 14 ctccacgtga acgctactta tgtgaattca agagattcac ataagtagcg ttcacgtgga 60 tttttggaa 69 <210> 15 <211> 25 <212> DNA <213> Artificial <220> <223> Target sequence in Mouse c-met <400> 15 tccacgtgaa cgctacttat gtgaa 25 <210> 16 <211> 63 <212> DNA <213> Artificial <220> <223> CRISPR gRNA SEQ for Human c-met <400> 16 aatttctact aagtgtagat aatttctact aagtgtagat cactccccat tgctcctctg 60 cac 63 <210> 17 <211> 23 <212> DNA <213> Artificial <220> <223> Target sequence in Human c-met <400> 17 gtgcagagga gcaatgggga gtg 23 <210> 18 <211> 3684 <212> DNA <213> Artificial <220> <223> Lbcpf1 SEQ <400> 18 atgagcaagc tggagaagtt tacaaactgc tactccctgt ctaagaccct gaggttcaag 60 gccatccctg tgggcaagac ccaggagaac atcgacaata agcggctgct ggtggaggac 120 gagaagagag ccgaggatta taagggcgtg aagaagctgc tggatcgcta ctatctgtct 180 tttatcaacg acgtgctgca cagcatcaag ctgaagaatc tgaacaatta catcagcctg 240 ttccggaaga aaaccagaac cgagaaggag aataaggagc tggagaacct ggagatcaat 300 ctgcggaagg agatcgccaa ggccttcaag ggcaacgagg gctacaagtc cctgtttaag 360 aaggatatca tcgagacaat cctgccagag ttcctggacg ataaggacga gatcgccctg gtgaacagct tcaatggctt taccacagcc ttcaccggct tctttgataa cagagagaat atgttttccg aggaggccaa gagcacatcc atcgccttca ggtgtatcaa cgagaatctg acccgctaca tctctatat ggacatcttc gagaaggtgg accgccatctt tgataagcac gaggtgcagg agatcaagga gaagatcctg aacagcgact atgatgtgga ggatttcttt gagggcgagt tctttaactt tgtgctgaca caggagggca tcgacgtgta taacgccatc 720 atcggcggct tcgtgaccga gagcggcgag aagatcaagg gcctgaacga gtacatcaac 780 ctgtataatc agaaaacca gcagaagctg cctaagttta agccactgta tagcaggtg ctgagcgatc gggagtctct gagcttctac ggcgagggct atacatccga tgaggaggtg ctggaggtgt ttagaaacac cctgaacaag aacagcgaga tcttcagctc catcaagaag ctggagaagc tgttcaagaa ttttgacgag tactctagcg ccggcatctt tgtgaagaac ggccccgcca tcagcacaat ctccaaggat atcttcggcg agtggaacgt gatccgggac 1080 1140 tacgaggacg atcggagaaa gtccttcaag aagatcggct ccttttctct ggagcagctg 1200 caggagatcg ccgacgccga tctgtctgtg gtggagaagc tgaagggagat catcatccag 1260 aaggtggatg agatctacaa ggtgtatggc tcctctgaga agctgtttcga cgccgatttt 1320 gtgctggaga agagcctgaa gaagaacgac gccgtggtgg ccatcatgaa ggacctgctg 1380 gattctgtga agagcttcga gaattacatc aaggccttct ttggcgaggg caaggaca 1440 aacagggacg agtccttcta tggcgatttt gtgctggcct acgacatcct gctgaaggtg 1500 gaccacatct acgatgccat ccgcaattat gtgacccaga agccctactc taggtaag 1560 ttcaagctgt attttcagaa ccctcagttc atgggcggct gggacaagga taggagaca 1620 gactatcggg ccaccatcct gagatacggc tccaagtact atctggccat catggataag 1680 aagtacgcca agtgcctgca gaagatcgac aagtacgatg tgaacggcaa ttacgagaag 1740 atcaactata agctgctgcc cggccctaat aagatgctgc caaaggtgtt cttttctaag 1800 aagtggatgg cctactataa ccccagcgag gacatccaga agatctacaa gaatggcaca 1860 ttcaagaagg gcgatatgtt taacctgaat gactgtcaca agctgatcga cttctttaag 1920 gatagcatct cccggtatcc aaagtggtcc aatgcctacg atttcaactt ttctgagaca 1980 gagaagtata aggacatcgc cggcttttac agagaggtgg aggagcaggg ctataaggtg 2040 agcttcgagt ctgccagcaa gaaggaggtg gataagctgg tggaggaggg caagctgtat 2100 atgttccaga tctataacaa ggacttttcc gataagtctc acggcacacc caatctgcac 2160 accatgtact tcaagctgct gtttgacgag aacaatcacg gacagatcag gctgagcgga 2220 ggagcagagc tgttcatgag gcgcgcctcc ctgaagaagg aggagctggt ggtgcaccca 2280 gccaactccc ctatcgccaa caagaatcca gataatccca agaaaaccac aaccctgtcc 2340 tacgacgtgt ataaggataa gaggttttct gaggaccagt acgagctgca catcccaatc 2400 gccatcaata agtgccccaa gaacatcttc aagatcaata cagaggtgcg cgtgctgctg 2460 aagcacgacg ataacccta tgtgatcggc atcgataggg gcgagcgcaa tctgctgtat 2520 atcgtggtgg tggacggcaa gggcaacatc gtggagcagt attccctgaa cgagatcatc 2580 aacaacttca acggcatcag gatcaagaca gattaccact ctctgctgga caagaaggag 2640 aaggagaggt tcgaggcccg ccagaactgg acctccatcg agaatatcaa ggagctgaag 2700 gccggctata tctctcaggt ggtgcacaag atctgcgagc tggtggagaa gtacgatgcc 2760 gtgatcgccc tggaggacct gaactctggc tttaagaata gccgcgtgaa ggtggagaag 2820 caggtgtatc agaagttcga gaagatgctg atcgataagc tgaactacat ggtggacaag 2880 aagtctaatc cttgtgcaac aggcggcgcc ctgaagggct atcagatcac caataagttc 2940 gagagcttta agtccatgtc tacccagaac ggcttcatct tttacatccc tgcctggctg 3000 acatccaaga tcgatccatc taccggcttt gtgaacctgc tgaaaaccaa gtataccagc 3060 atcgccgatt ccaagaagtt catcagctcc tttgacagga tcatgtacgt gcccgaggag 3120 gatctgttcg agtttgccct ggactataag aacttctctc gcacagacgc cgattacatc 3180 aagaagtgga agctgtactc ctacggcaac cggatcagaa tcttccggaa tcctaagaag 3240 aacaacgtgt tcgactggga ggaggtgtgc ctgaccagcg cctataagga gctgttcaac 3300 aagtacggca tcaattatca gcagggcgat atcagagccc tgctgtgcga gcagtccgac 3360 aaggccttct actctagctt tatgccctg atgagcctga tgctgcagat gcggaacagc 3420 atcacaggcc gcaccgacgt ggattttctg atcagccctg tgaagaactc cgacggcatc 3480 ttctacgata gccggaacta tgaggcccag gagaatgcca tcctgccaaa gaacgccgac 3540 gccaatggcg cctataacat cgccagaaag gtgctgtggg ccatcggcca gttcaagaag 3600 gccgaggacg agaagctgga taaggtgaag atcgccatct ctaacaagga gtggctggag 3660 tacgcccaga ccagcgtgaa gcac 3684 <210> 19 <211> 45 <212> DNA <213> Artificial <220> <223> linker sequence for IL-12 <400> 19 ggtggcggtg gctcgggcgg tggtgggtcg ggtggcggcg gatct 45 <210> 20 <211> 582 <212> DNA <213> Artificial <220> <223> lRES sequence <400> 20 gcccccccc ctaacgttac tggccgaagc cgcttggaat aaggccggtg tgcgtttgtc 60 tatatgttat tttccaccat attgccgtct tttggcaatg tgagggcccg gaaacctggc 120 cctgtcttct tgacgagcat tcctagctag gggtctttcc cctctcgcca aaggaatgca 180 aggtctgttg aatgcgtga aggaagcagt tcctctggaa gcttcttgaa gacaaacaac 240 gtctgtagcg accctttgca ggcagcggaa ccccccacct ggcgacaggt gcctctgcgg 300 ccaaaagcca cgtgtataag atacacctgc aaaggcggca caaccccagt gccacgttgt 360 gagttggata gttgtggaaa gagtcaaatg gctctcctca agcgtattca acaaggggct 420 gaaggatgcc cagaaggtac cccattgtat gggatctgat ctggggcctc ggtgcacatg 480 ctttacatgt gtttagtcga ggttaaaaaa acgtctaggc cccccgaacc acggggacgt 540 ggttttcctt tgaaaaacac gatgataata tggccacaac ca 582
Claims
1. An adenovirus system, comprising: Interleukin 12 (IL-12) encoding gene, which includes IL-12A (p35) gene sequence and IL-12B (p40) gene sequence; and A gene expressing an oligonucleotide that is complementary to the mRNA of C-met and inhibits the expression of C-met.
2. The adenovirus system according to claim 1, characterized in that The interleukin 12 (IL-12) encoding gene further includes a linker sequence or an internal ribosome entry site (IRES) sequence between the IL-12A (p35) gene sequence and the IL-12B (p40) gene sequence.
3. The adenovirus system according to claim 1, characterized in that The interleukin 12 (IL-12) encoding gene is inserted into the E1B or E3 region of the adenovirus gene in the adenovirus system.
4. The adenovirus system according to claim 1, characterized in that The oligonucleotide that complementarily binds to the mRNA of C-met to inhibit the expression of C-met is one or more selected from the group including small hairpin RNA (shRNA), miRNA, siRNA, antisense oligonucleotide, ribozyme, deoxyribozyme, peptide nucleic acid (PNA) and CRISPR guide RNA.
5. The adenovirus system according to claim 1, characterized in that The gene encoding the oligonucleotide that inhibits C-met expression is inserted into the E1B or E3 region of the adenovirus gene in the adenovirus system. The adenovirus system according to claim 1 , wherein the adenovirus system is a recombinant adenovirus or a recombinant adenovirus DNA.
7. The adenovirus system according to claim 1, characterized in that When the oligonucleotide that complementarily binds to the mRNA of C-met to inhibit the expression of C-met is the guide RNA of CRISPR, the adenovirus system also includes a nucleotide sequence that expresses the Cas protein.
8. The adenovirus system according to claim 1, characterized in that Also included are biocompatible polymers in combination with the adenoviral system.
9. The adenovirus system according to claim 8, characterized in that The biocompatible polymer is selected from PEI-Arg-mPEG-SS-mPEG-Arg-PEI (PAPS), mPEG-PEI-g-Arg-SS-Arg-g-PEI-mPEG (PPSA), catechol-grafted polylysine (PICION) cross-linked with PEGylated and iron oxide nanoparticles, arginine-grafted biodegradable polymer (ABP), PEGylated and PTX-conjugated polymer micelles (APP), mPEG-b-Pip-CBA (PPCBA), PPCBA-PEI-arginine (PPA), poly(amidoamine) dendrimers (PAMAM), polyethylene glycol (PEG), polylactide (PLA), polyglycolide (PGA), polyglycolic acid (PLGA), poly-ε-caprolactone (PCL), polyethyleneimine (PEI), hyaluronic acid (HA), gelatin, chitosan and serum albumin.
10. An anticancer composition comprising the adenoviral system according to any one of claims 1 to 9.
11. The anticancer composition according to claim 10, characterized in that The composition is administered intratumorally.
12. A composition for enhancing anti-tumor immunity, comprising the adenoviral system according to any one of claims 1 to 9.
13. The composition for enhancing anti-tumor immunity according to claim 12, characterized in that: The composition is administered intratumorally.
